

CITATION REPORT

List of articles citing

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

DOI: 10.1016/s1470-2045(17)30074-8
Lancet Oncology, The, 2017, 18, e143-e152.

Source: <https://exaly.com/paper-pdf/66097384/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1352	irRECIST and iRECIST: the devil is in the details. 2017 , 28, 1676-1678		21
1351	A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors. 2017 , 13, 1765-1767		2
1350	RECISTing the Temptation to Prematurely Stop Nivolumab. 2017 , 72, 377-378		
1349	Toward common response evaluation criteria for solid tumors and lymphomas: RECIL and RECIST?. 2017 , 28, 1409-1411		2
1348	Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges. 2017 , 3, 391-406		161
1347	iRECIST: A clarification of tumour response assessment in the immunotherapy era. 2017 , 77, 165-167		15
1346	Future cancer research priorities in the USA: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2017 , 18, e653-e706	21.7	106
1345	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. 2017 , 9, 995-1004		10
1344	Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential. 2017 , 9, 627-636		8
1343	Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. 2017 , 120, 13-21		46
1342	Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. 2017 , 28, 3044-3050		87
1341	Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma. 2017 , 77, 1645-1655		4
1340	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. 2017 , 18, 1477-1490		16
1339	[Radiological response assessment of modern immunotherapy using iRECIST]. 2017 , 57, 826-833		2
1338	Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. 2017 , 6, e1371896		33
1337	Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. 2017 , 113, 4-6		37
1336	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. 2017 , 23, 4950-4958		30

1335	Évaluation thérapeutique des tumeurs solides [Session 6]. 2017 , 41, 367-370	
1334	Évaluation de la réponse thérapeutique après traitement par inhibiteurs des checkpoints (anticorps monoclonaux immunomodulateurs). 2017 , 41, 307-312	
1333	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. 2017 , 59, 71-78	65
1332	The new era of cancer immunotherapy: what can molecular imaging do to help?. 2017 , 5, 299-301	7
1331	Immunotherapy in Non-Small Cell Lung Cancer Treatment: Current Status and the Role of Imaging. 2017 , 32, 300-312	35
1330	Targeting immune checkpoints in breast cancer: an update of early results. 2017 , 2, e000255	79
1329	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. 2017 , 23, 5737-5744	55
1328	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. 2017 , 14, 655-668	498
1327	Cancer bronchique non ^petites cellules de stade IV sans addiction oncogñique : traitements en 2 e ligne et au-del^ . 2017 , 9, 248-258	
1326	Immuntherapie in der Onkologie. 2017 , 12, 17-33	1
1325	Breast Cancer Vaccines: New Insights. 2017 , 8, 270	22
1324	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. 2017 , 1, 179-187	1
1323	A practical guide to the handling and administration of talimogene laherparepvec in Europe. 2017 , 10, 3867-3880	24
1322	Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?. 2017 , 15, 134	112
1321	The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). 2017 , 36, 192	13
1320	Proceedings of the International Cancer Imaging Society (ICIS) 17th Annual Teaching Course. 2017 , 17,	1
1319	Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges. 2017 , 1, 107-114	8
1318	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. 2017 , 7,	12

1317	Impact of Variability in Portal Venous Phase Acquisition Timing in Tumor Density Measurement and Treatment Response Assessment: Metastatic Colorectal Cancer as a Paradigm. 2017 , 1, 1-8		11
1316	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. 2018 , 4, 522-528		56
1315	Results and challenges of immune checkpoint inhibitors in colorectal cancer. 2018 , 18, 561-573		38
1314	Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. 2018 , 14, 1547-1558		3
1313	Immunotherapy in Lung Cancer and the Role of Imaging. 2018 , 39, 314-321		2
1312	The role of interim F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. 2018 , 45, 1289-1296		64
1311	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. 2018 , 233, 6337-6343		65
1310	Pitfalls in the radiological response assessment of immunotherapy. 2018 , 11, 138-143		45
1309	A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non-Small Cell Lung Cancer Based on Early Tumor Kinetics. 2018 , 24, 3292-3298		22
1308	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. <i>Lancet Oncology, The</i> , 2018 , 19, 812-824	21.7	70
1307	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. 2018 , 126, 135-144		12
1306	Immunotherapy and the role of imaging. 2018 , 124, 2906-2922		48
1305	Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. 2018 , 56, 485-495		42
1304	Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. 2018 , 51,		7
1303	[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]. 2018 , 35, 197-205		3
1302	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. <i>Lancet Oncology, The</i> , 2018 , 19, 229-239	21.7	82
1301	Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. 2018 , 7, e1424675		36
1300	Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review. 2018 , 10, 139-148		10

1299	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. <i>Lancet Oncology, The</i> , 2018 , 19, e20-e32	21.7	63
1298	PD-1 Blockade in Renal Cell Carcinoma. 2018 , 345-355		
1297	Advanced PET imaging in oncology: status and developments with current and future relevance to lung cancer care. 2018 , 30, 77-83		7
1296	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. 2018 , 24, 2268-2275		53
1295	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. 2018 , 52, 158-165		4
1294	Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer. 2018 , 30, 98-104		3
1293	Pushing the limits of immune-related response: a case of "extreme pseudoprogression". 2018 , 67, 1105-1111		14
1292	The current evidence for a biomarker-based approach in cancer of unknown primary. 2018 , 67, 21-28		25
1291	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. 2018 , 96, 91-104		73
1290	Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy. 2018 , 9, 41-50		7
1289	The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST. 2018 , 104, 88-95		11
1288	MR Imaging of Tumor-Associated Macrophages: The Next Frontier in Cancer Imaging. 2018 , 11, 1178623X18771074		1074
1287	Criterios específicos de respuesta tumoral. 2018 , 60, 64-81		2
1286	[Immunotherapy with checkpoint inhibitors in local advanced and metastatic urothelial carcinoma]. 2018 , 49, 142-156		2
1285	Diseases of the Abdomen and Pelvis 2018-2021. 2018 ,		8
1284	Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer. 2018 , 36, 1703-1709		45
1283	Immunotherapy: Immune-modified response criteria - an iterative learning process?. 2018 , 15, 267-268		4
1282	Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution. 2018 , 41, 549-556		29

1281	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. 2018 , 34, 840-852	16
1280	Immune Modulation Therapy and Imaging: Workshop Report. 2018 , 59, 410-417	19
1279	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. 2018 , 24, 730-736	8
1278	Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma. 2018 , 13, e1-e2	3
1277	Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls. 2018 , 130, 85-91	68
1276	Immune-related tumour response assessment criteria: a comprehensive review. 2018 , 91, 20170457	38
1275	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. 2018 , 88, 38-47	178
1274	Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study. 2018 , 81, 333-337	5
1273	Veterinary Oncology Immunotherapies. 2018 , 48, 257-277	6
1272	Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab. 2018 , 90, 146-148	3
1271	Reviewing RECIST in the Era of Prolonged and Targeted Therapy. 2018 , 13, 154-164	15
1270	Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. 2018 , 80, 304-316	22
1269	Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. 2018 , 19, 175-180	1
1268	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. 2018 , 1-28	
1267	SEOM clinical guideline for treatment of kidney cancer (2017). 2018 , 20, 47-56	10
1266	Absolute number of new lesions on F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. 2018 , 45, 376-383	105
1265	Osteoblastic bone response mimicking bone progression during treatment with pembrolizumab in advanced cutaneous melanoma. 2018 , 29, 1026-1029	4
1264	Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. 2018 , 38, 1008-1018	34

1263	Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology. 2018 , 2, 1-12	7
1262	New Era in the Management of Melanoma Brain Metastases. 2018 , 38, 741-750	28
1261	Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. 2018 , 38, 1019-1029	32
1260	Imaging Advances in the Management of Kidney Cancer. 2018 , JCO2018791236	7
1259	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. 2018 , 36, 850-858	184
1258	Patterns of Response and Progression to Immunotherapy. 2018 , 38, 169-178	128
1257	Global Challenges for Cancer Imaging. 2018 , 4, 1-10	10
1256	Full Issue PDF Volume 33, Issue 6. 2018 , 33, 1-84	
1255	Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy. 2018 , 10, 1124-1128	37
1254	Do immune checkpoint inhibitors need new studies methodology?. 2018 , 10, S1564-S1580	35
1253	Radiologic presentation of non-small cell lung cancer treated with anti-PD-1 therapy. 2018 , 10, S3930-S3932	1
1252	Immunonkologie von Kopf-Hals-Tumoren. 2018 , 13, 336-349	
1251	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. 2018 , 52, 365-369	27
1250	Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. 2018 , 11, 278-287	13
1249	Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. 2018 , 25, e373-e384	61
1248	T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. 2018 , 8, 6070-6087	22
1247	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. 2018 , 5, 351	37
1246	Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. 2018 , 6, 130	8

1245	The role of radiology in the evaluation of the immunotherapy efficacy. 2018 , 10, S1438-S1446	17
1244	Response to PD1 inhibition in conventional chondrosarcoma. 2018 , 6, 94	21
1243	Immunotherapy beyond progression in advanced renal cell carcinoma: a case report and review of the literature. 2018 , 10, 1123-1132	8
1242	PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer. 2018 , 11, 5973-5989	59
1241	Adverse effects and radiological manifestations of new immunotherapy agents. 2019 , 92, 20180164	6
1240	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv192-iv237	897
1239	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv238-iv255	355
1238	Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT). 2018 , 29, 2163-2174	88
1237	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. 2018 , 70, 232-244	28
1236	Role of noninvasive molecular imaging in determining response. 2018 , 3, 534-547	17
1235	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. 2018 , 13, 1906-1918	50
1234	Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement. 2018 , 6, 108	11
1233	Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. 2018 , 10, 4333-4347	22
1232	Hyperprogressive disease: recognizing a novel pattern to improve patient management. 2018 , 15, 748-762	206
1231	[Tumour assessment criteria for immune checkpoint inhibitors]. 2018 , 35, 828-845	2
1230	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. 2018 , 9, 8706-8715	52
1229	[Tumor assessment in immune checkpoint inhibitor therapy : Tumor response, progression and pseudoprogression]. 2018 , 57, 1316-1325	2
1228	Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma. 2018 , 13, 543-554	23

1227	Advances in oncological treatment: limitations of RECIST 1.1 criteria. 2018 , 62, 129-139	15
1226	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. 2018 , 4, 1543-1552	380
1225	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. 2018 , 78, 1443-1457	41
1224	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. 2018 , 11, 185-192	4
1223	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. 2018 , 29, 2175-2182	13
1222	Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy. 2018 , 6, 417-427	5
1221	[Imaging in individualized uro-oncology]. 2018 , 57, 1048-1057	
1220	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. 2018 , 379, e14	89
1219	Zielgerichtete Therapien. 2018 ,	
1218	Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. 2018 , 13, 978-986	60
1217	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661	133
1216	Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1). 2018 , 13, 1012-1021	40
1215	Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. 2018 , 67, 1317-1324	4
1214	Imaging for the diagnosis and response assessment of renal tumours. 2018 , 36, 1927-1942	35
1213	The changing scenario of 1 line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. 2018 , 130, 1-12	16
1212	Real-World Pseudoprogression: an Uncommon Phenomenon. 2018 , 13, 880-882	9
1211	Combination of checkpoint inhibitors with other agents as a strategy to improve anti-cancer effect - a glimpse to the future. 2018 , 27, 569-572	4
1210	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. 2018 , 1, e180416	30

1209	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. 2018 , 6, 44	39
1208	Immunotherapy treatment: an issue for metabolic response. 2018 , 62, 140-151	4
1207	The Mediastinal Mass. 2018 ,	
1206	PACIFIC: Time for a surgical IIIA uprising. 2018 , 156, 1249-1254	3
1205	Loss of heterozygosity of key tumor suppressor genes in advanced renal cancer patients treated with nivolumab. 2018 , 10, 743-752	1
1204	Pseudoprogession of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment. 2018 , 13, 882-885	8
1203	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. 2018 , 10, 1758835918777427	5
1202	Nivolumab use for gene mutation carriers with recurrent epithelial ovarian cancer: A case series. 2018 , 25, 98-101	19
1201	Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. 2018 , 130, 13-26	20
1200	Hyperprogression as a distinct outcome after immunotherapy. 2018 , 70, 16-21	69
1199	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. 2018 , 20, 696-704	23
1198	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. 2018 , 6, 8	606
1197	Pseudoprogession manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. 2018 , 6, 24	9
1196	Immuntherapie mit Checkpoint-Inhibitoren beim lokal fortgeschrittenen und metastasierten Urothelzellkarzinom. 2018 , 39, 307-320	
1195	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. 2018 , 144, 2245-2261	16
1194	From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting. 2018 , 12, 1661-1672	23
1193	Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?. 2018 , 21, 419-430	1
1192	Longitudinal studies of the F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. 2018 , 67, 1261-1270	19

1191	SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. 2018 , 17, 527-540	4
1190	Clinical outcomes of African American patients with advanced or metastatic non-small cell lung cancer on Nivolumab in a single community-based cancer center. 2018 , 35, 109	7
1189	Pseudoprogession in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab. 2019 , 55, 168-169	
1188	Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. 2019 , 68, 813-822	39
1187	A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors. 2019 , 48, 576-585	14
1186	F-FDG PET/CT for response assessment in Hodgkin lymphoma undergoing immunotherapy with checkpoint inhibitors. 2019 , 60, 367-375	19
1185	To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade. 2019 , 25, 663-673	7
1184	Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events. 2019 , 2019, 1856594	8
1183	Successful combination therapy of systemic checkpoint inhibitors and intralesional interleukin-2 in patients with metastatic melanoma with primary therapeutic resistance to checkpoint inhibitors alone. 2019 , 68, 1417-1428	14
1182	Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. 2019 , 7, 2515135519862234	14
1181	Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?. 2019 , 11, 1149-1160	8
1180	Challenges of international oncology trial collaboration-a call to action. 2019 , 121, 515-521	10
1179	Role of medical imaging for immune checkpoint blockade therapy: From response assessment to prognosis prediction. 2019 , 8, 5399-5413	12
1178	Biomarkers of hyperprogression and pseudoprogession with immune checkpoint inhibitor therapy. 2019 , 15, 2645-2656	6
1177	A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229). 2019 , 24, 1439-1445	21
1176	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). 2019 , 7, 184	223
1175	State of the Art of Natural Killer Cell Imaging: A Systematic Review. 2019 , 11,	6
1174	A case report of pseudo-progression after pembrolizumab in metastatic gastric cancer and a review of immunotherapy in gastroesophageal tumors. 2019 , 12, 51-59	

1173	A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). 2019 , 17, 356-365.e1	8
1172	Immunonkologische Anzeige beim Mammakarzinom. 2019 , 52, 343-353	2
1171	Pseudoprogression presenting as intestinal perforation in non-small cell lung cancer treated with anti-PD-1: A case report. 2019 , 11, 132-134	6
1170	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. 2019 , 11, 1758835919842692	36
1169	Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. 2019 , 46, 2298-2310	55
1168	The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials. 2019 , 9, 634	2
1167	Advanced urothelial cancer: a radiology update. 2019 , 44, 3858-3873	3
1166	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. 2019 , 125, 3208-3218	44
1165	Lymph node metastasis matters. 2019 , 11, S331-S333	1
1164	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology, The</i> , 2019 , 20, e378-e389	21.7 88
1163	Current Immunotherapy Practices in Melanoma. 2019 , 28, 403-418	8
1162	Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. 2019 , 39, 998-1016	8
1161	Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. 2019 , 213, 1232-1239	3
1160	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. 2019 , 20, 68	16
1159	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. 2019 , 11,	25
1158	Imaging of T-cells and their responses during anti-cancer immunotherapy. 2019 , 9, 7924-7947	50
1157	Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis. 2019 , 11,	54
1156	Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. 2019 , 11, 1718-1731	9

1155	Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. 2019 , 8, 7669-7678	16
1154	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. 2019 , 11,	24
1153	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. 2019 , 7, 302	36
1152	Single or combined immune checkpoint inhibitors compared to first-line chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. 2019 ,	2
1151	[Influence of immunomodulators on urological imaging]. 2019 , 58, 1451-1460	
1150	Use of circulating tumoral DNA to guide treatment for metastatic melanoma. 2019 , 20, 1259-1270	5
1149	Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma. 2019 , 32, e13107	0
1148	Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis. 2019 , 21, 1064-1080	4
1147	Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. 2019 , 12, 6023-6032	15
1146	Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyondPart 2. 2019 , 02, 107-115	1
1145	Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyondPart 1. 2019 , 02, 098-106	0
1144	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. 2019 , 59, 290-297	53
1143	Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. 2019 , 7, 235	6
1142	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. 2019 , 20,	10
1141	Phase 1 trials as valid therapeutic options for patients with cancer. 2019 , 16, 773-778	43
1140	Immunotherapy and urothelial carcinoma: An overview and future prospectives. 2019 , 143, 46-55	15
1139	Best Practice in Systemic Therapy for Head and Neck Squamous Cell Carcinoma. 2019 , 9, 815	31
1138	Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. 2019 , 7, 253	50

1137	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. 2019 , 17, e1181-e1184	
1136	Chemoimmunotherapy for stage IV non-small-cell lung cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2019 , 20, e467	21.7
1135	The Proceedings of the 19th International Cancer Imaging Society Meeting and Annual Teaching Course : Verona, Italy. 7 - 9 October 2019. 2019 , 19, 62	
1134	Hyperprogressive disease with immunotherapy: new directions. 2019 , 11, S1877-S1880	5
1133	Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. 2019 , 39, 1923-1937	48
1132	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. 2019 , 25, 2174-2184	47
1131	Immune checkpoint inhibitors and non-small-cell lung cancer management: 2018 update. 2019 , 11, 149-153	5
1130	[Immuno-oncology of head and neck tumors]. 2019 , 67, 221-235	1
1129	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. 2019 , 68, 553-561	32
1128	Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. 2019 , 109, 21-27	121
1127	Immunotherapy for genitourinary tumors. 2019 , 26, 326-333	6
1126	Novel patterns of response under immunotherapy. 2019 , 30, 385-396	194
1125	Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. 2019 , 8,	10
1124	Advancing Drug Development in Gynecologic Malignancies. 2019 , 25, 4874-4880	10
1123	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma. 2019 , 13, 615-621	3
1122	Mesothelioma. 2019 ,	1
1121	F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. 2019 , 46, 1859-1868	35
1120	Monitoring efficacy of checkpoint inhibitor therapy in patients with non-small-cell lung cancer. 2019 , 11, 769-782	6

1119	Hyperprogression during immunotherapy: do we really want to know?. 2019 , 30, 1028-1031	11
1118	Intra-individual consistency of spectral detector CT-enabled iodine quantification of the vascular and renal blood pool. 2019 , 29, 6581-6590	10
1117	Cancer Immunotherapies. 2019 , 49, 881-902	12
1116	Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study. 2019 , 134, 59-65	17
1115	Imaging in Lung Cancer. 2019 , 7, 1	
1114	Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab. 2019 , 11, 81-90	17
1113	Assessment of Subcutaneous vs Intravenous Administration of Anti-PD-1 Antibody PF-06801591 in Patients With Advanced Solid Tumors: A Phase 1 Dose-Escalation Trial. 2019 , 5, 999-1007	27
1112	PD-L1 detection using Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab response. 2019 , 7, 144	32
1111	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. 2019 , 37, 2738-2745	82
1110	Hyperprogression under Immunotherapy. 2019 , 20,	63
1109	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. 2019 , 6, 113	13
1108	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. 2019 , 104, 828-835	22
1107	Imaging of Activated T Cells as an Early Predictor of Immune Response to Anti-PD-1 Therapy. 2019 , 79, 3455-3465	34
1106	Quantitative Multiparametric MRI May Augment the Response to Radiotherapy in Mid-Treatment Assessment of Patients with Esophageal Carcinoma. 2019 , 42, 326-333	2
1105	Going to extremes: determinants of extraordinary response and survival in patients with cancer. 2019 , 19, 339-348	17
1104	Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. 2019 , 39, 352-363	14
1103	Modified core-shell magnetic mesoporous zirconia nanoparticles formed through a facile "outside-to-inside" way for CT/MRI dual-modal imaging and magnetic targeting cancer chemotherapy.. 2019 , 9, 13220-13233	9
1102	Unique Case of Pseudoprogression Manifesting as Lung Cavitation After Pembrolizumab Treatment. 2019 , 14, e108-e109	13

1101	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. 2019 , 25, 920-928	302
1100	Meningeal enhancement depicted by magnetic resonance imaging in tumor patients: neoplastic meningitis or therapy-related enhancement?. 2019 , 61, 775-782	4
1099	Hyperprogressive disease: a distinct effect of immunotherapy?. 2019 , 11, S262-S265	11
1098	PD1/PD-L1 inhibitor treatment for late stage non-small cell lung carcinoma, sometimes does more harm than good!. 2019 , 11, S396-S398	2
1097	Concerns Regarding Phase 1b Clinical Trial of Atezolizumab Plus nab-Paclitaxel for Metastatic Breast Cancer. 2019 , 5, 908	
1096	Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIA non-small-cell lung cancer (NSCLC): the NEOMUN trial. 2019 , 19, 413	33
1095	A network approach to developing immuno-oncology combinations in Canada. 2019 , 26, 73-79	
1094	Immune checkpoint inhibition for the treatment of mesothelioma. 2019 , 19, 697-706	15
1093	Efficacy and Safety Analysis of Neli pepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial. 2019 , 25, 4248-4254	58
1092	Implications of Immunotherapy in Hepatobiliary Tumors. 2019 , 35, 18-26	4
1091	Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. 2019 , 37, 72-80	12
1090	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. 2019 , 20,	41
1089	Early assessment with F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. 2019 , 19, 298	13
1088	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. 2019 , 143, 63-144	26
1087	How rapid advances in imaging are defining the future of precision radiation oncology. 2019 , 120, 779-790	28
1086	Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma. 2019 , 36, 35	3
1085	Electromagnetic Navigation Placement of Intratumoral Gold Fiducials for Stereotactic Radiation Therapy in Lung Cancer. 2019 , 55, 169-171	
1084	Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST. 2019 , 9, 8	69

1083	KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer. 2019 , 110, 1012-1020	29
1082	Meeting the Challenge of Targeting Cancer Stem Cells. 2019 , 7, 16	73
1081	The potential of breath analysis to improve outcome for patients with lung cancer. 2019 , 13, 034002	20
1080	Stereophotogrammetric three-dimensional photography is an accurate and precise planimetric method for the clinical visualization and quantification of human papilloma virus-induced skin lesions. 2019 , 33, 1506-1512	2
1079	Phase 1 Open-Label, Multicenter Study of First-in-Class ROR1 Agonist LYC-55716 (Cintirorgon): Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. 2019 , 25, 3508-3516	23
1078	PET/CT in Pediatric Oncology. 2019 , 29-61	1
1077	Tumor Response Assessment: RECIST and Beyond. 2019 , 157-169	1
1076	Immunotherapy of Melanoma: Facts and Hopes. 2019 , 25, 5191-5201	110
1075	Imaging in Pediatric Oncology. 2019 ,	2
1074	Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer. 2019 , 26, e81-e93	20
1073	A Rare Delayed Atypical Pseudoprogression in Nivolumab-Treated Non-Small-Cell Lung Cancer. 2019 , 2019, 8356148	2
1072	RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. 2019 , 37, 1102-1110	24
1071	Atypical Response Patterns in Patients Treated With Nivolumab. 2019 , 1-5	15
1070	Current Landscape of Immunotherapy in Breast Cancer: A Review. 2019 , 5, 1205-1214	143
1069	Are we ready to describe response or progression to immunotherapy in lung cancer?. 2019 , 138, 112-119	5
1068	Translating preclinical MRI methods to clinical oncology. 2019 , 50, 1377-1392	19
1067	TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. 2020 , 112, 38-45	8
1066	First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers. 2019 , 19, 279	27

1065	Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival. 2019 , 70, 1262-1277	90
1064	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. 2019 , 7, 93	79
1063	Immune check-point in glioblastoma multiforme. 2019 , 138, 60-69	10
1062	Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue. 2019 , 11, 365-368	
1061	Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. 2019 , 20, 178-185.e2	23
1060	Pseudoprogession in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?. 2019 , 14, 328-331	23
1059	Nivolumab-refractory patients with advanced non-small-cell lung cancer. 2019 , 130, 128-134	12
1058	Directional inconsistency between Response Evaluation Criteria in Solid Tumors (RECIST) time to progression and response speed and depth. 2019 , 109, 196-203	6
1057	Pseudoprogession on treatment with immune-checkpoint inhibitors in patients with gastrointestinal malignancies: Case series and short literature review. 2019 , 43, 487-494	5
1056	Pseudoprogession in a Patient with Metastatic Lung Adenocarcinoma Treated with Nivolumab. 2019 , 55, 168-169	0
1055	Immune-checkpoint inhibitors and candidate surrogate endpoints for overall survival across tumour types: A systematic literature review. 2019 , 137, 35-42	9
1054	Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogession and hyperprogession in decision making for patients' treatment. 2019 , 11, 35-38	16
1053	Curative effect assessment of immunotherapy for non-small cell lung cancer: The "blind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST). 2019 , 10, 587-592	8
1052	Immunotherapy and radiotherapy for metastatic cancers. 2019 , 8, 312-325	21
1051	Integrating Small Animal Irradiators with Functional Imaging for Advanced Preclinical Radiotherapy Research. 2019 , 11,	11
1050	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. 2019 , 125, 1341-1349	78
1049	Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis. 2019 , 5,	7
1048	Computed Tomography-Derived Radiomic Metrics Can Identify Responders to Immunotherapy in Ovarian Cancer. 2019 , 3,	11

1047	A sobering "check" on immune checkpoint inhibitors. 2019 , 134, 1366-1367	
1046	How to recognize and manage hyper-progression and pseudo- progression during immune checkpoint blockade in non-small cell lung cancer. 2019 , 2, 35-35	1
1045	PET Assessment of Immune Effects from Interventional Oncology Procedures. 2019 , 14, 477-485	3
1044	iRECIST pour (pas seulement) les nuls. 2019 , 2, 83-87	
1043	Best first-line therapy for patients with advanced non-small cell lung cancer, performance status 2 without a targetable mutation or with an unknown mutation status. 2019 ,	78
1042	Immune checkpoint inhibitors for unresectable hepatocellular carcinoma. 2019 ,	78
1041	Atypisches Ansprechen mit Pseudoprogression im Knochen unter Nivolumab bei einem Patienten mit fortgeschrittenem kutanem Plattenepithelkarzinom. 2019 , 7, 149-153	
1040	Evaluation of Traditional Chinese Medicine Herbs in Oncology Clinical Trials. 2019 , 25, 367-371	7
1039	Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. 2019 , 1, e190031	9
1038	Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. 2019 , 9, 18069	4
1037	Tumour pseudoprogression during nivolumab immunotherapy for lung cancer. 2019 , 61, 498-505	1
1036	ES09.02 How I Report Imaging for Assessment of Responses to Targeted Therapies vs. Immune Checkpoint Inhibitors vs. Chemotherapy. 2019 , 14, S35-S36	
1035	Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer. 2019 , 44, 535-543	28
1034	Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen. 2019 , 98, e16754	5
1033	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). 2019 , 7, 354	100
1032	Predicting Response to Immunotherapy by Evaluating Tumors, Lymphoid Cell-Rich Organs, and Immune-Related Adverse Events Using FDG-PET/CT. 2019 , 44, e272-e279	51
1031	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. 2019 , 98, e16417	18
1030	Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study. 2019 , 7, 337	45

1029	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. 2019 , 28, 109-119	8
1028	Gynecologic Malignancies. 2019 , 135-155	
1027	The Cancer Immunogram: A Pledge for a Comprehensive Biomarker Approach for Personalized Immunotherapy in Urothelial Cancer. 2019 , 75, 445-447	7
1026	Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS. 2019 , 30, 171-210	121
1025	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. 2019 , 16, 241-255	39
1024	Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond. 2019 , 18, 145-165	24
1023	F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. 2019 , 60, 335-341	78
1022	PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade. 2019 , 120, 3-5	48
1021	Progression-free survival in oncology: Caveat emptor!. 2019 , 124, 240-244	3
1020	Exaggeration of PFS by blinded, independent, central review (BICR). 2019 , 30, 332-338	8
1019	Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials. 2019 , 106, 1-11	16
1018	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. 2019 , 290, 9-22	95
1017	Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series. 2019 , 11, 167-175	21
1016	Neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer: a feasibility and safety study. 2019 , 17, 14	11
1015	The Response Evaluation Criteria in Solid Tumors (RECIST). 2019 , 501-511	5
1014	Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. 2019 , 6, e48-e57	109
1013	Safety and efficacy of immune checkpoint inhibitors for end-stage renal disease patients undergoing dialysis: a retrospective case series and literature review. 2019 , 37, 579-583	15
1012	FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. 2019 , 46, 238-250	130

1011	Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. 2019 , 25, 946-956	67
1010	Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy. 2019 , 48, 142-147	9
1009	HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA liver metastases. 2020 , 27, 341-355	24
1008	Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer. 2020 , 22, 21-36	20
1007	Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. 2020 , 82, 311-316	30
1006	Prognostic and predictive molecular biomarkers in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors: a systematic review. 2020 , 20, 169-185	10
1005	Tumor Liquid Biopsies. 2020 ,	5
1004	Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy. 2020 , 25, 33-45	54
1003	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. 2020 , 22, 17-30	43
1002	Heterogeneity of Hepatocellular Carcinoma on Imaging. 2020 , 40, 61-69	5
1001	Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. 2020 , 27, e10-e18	6
1000	Principles of Immunotherapy in Melanoma. 2020 , 100, 161-173	17
999	Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review. 2020 , 139, 18-21	4
998	Image Guided Dermatologic Treatments. 2020 ,	0
997	Atlas of Response to Immunotherapy. 2020 ,	
996	Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive F-FDG-PET. 2020 , 10, 925-937	26
995	Changes in the neutrophil-to-lymphocyte ratio during nivolumab monotherapy are associated with gastric cancer survival. 2020 , 85, 265-272	23
994	Therapy Response Imaging in Oncology. 2020 ,	

993	Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models. 2020 , 26, 1787-1795		27
992	iRECIST: how to do it. 2020 , 20, 2		20
991	Imaging of Novel Oncologic Treatments in Lung Cancer Part 1: Systemic Therapies. 2020 , 35, 26-36		3
990	F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Assessing Tumor Response to Immunotherapy in Solid Tumors: Melanoma and Beyond. 2020 , 15, 11-22		12
989	Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. 2020 , 122, 108743		4
988	Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. 2020 , 61, 983-991		5
987	Molecular imaging biomarkers for immune checkpoint inhibitor therapy. 2020 , 10, 1708-1718		35
986	Comparison Between F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. 2020 , 61, 990-998		30
985	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 121-133	21.7	93
984	Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. 2020 , 100, 104477		6
983	Challenges in assessing solid tumor responses to immunotherapy. 2020 , 27, 528-538		13
982	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. 2020 , 26, 1846-1855		35
981	FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns. 2020 , 47, 1158-1167		43
980	Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of F-FDG PET/CT. 2020 , 61, 821-826		38
979	CAR T-Cell Therapy for CNS Malignancies. 2020 , 165-198		
978	Criteria of metabolic response to immunotherapy. 2020 , 39, 51-56		
977	Exploring Essential Issues for Improving Therapeutic Cancer Vaccine Trial Design. 2020 , 12,		4
976	Nivolumab in pre-treated malignant pleural mesothelioma: real-world data from the Dutch expanded access program. 2020 , 9, 1169-1179		16

975	Positron Emission Tomography for Response Evaluation in Microenvironment-Targeted Anti-Cancer Therapy. 2020 , 8,	1
974	Treatment after progression in the era of immunotherapy. <i>Lancet Oncology, The</i> , 2020 , 21, e463-e476	21.7 50
973	Baseline IFN- γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. 2020 , 10, 17626	3
972	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. 2020 , 8,	11
971	Immunotherapy for Renal Cell Carcinoma. 2020 ,	
970	Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. 2020 , 26, 6445-6452	8
969	Dissociated Response in Metastatic Cancer: An Atypical Pattern Brought Into the Spotlight With Immunotherapy. 2020 , 10, 566297	11
968	Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. 2020 , 111, 105013	3
967	PD-1 blockade in extranodal NK/T-cell lymphoma: who is in charge?. 2020 , 34, 3432-3433	1
966	Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma. 2020 , 13, 100829	4
965	Recent developments in head and neck melanoma. 2020 , 28, 258-262	2
964	Rational use of F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. 2020 , 153, 103044	12
963	Long-term durable responses after pembrolizumab immunotherapy for recurrent, resistant endometrial cancer. 2020 , 33, 100581	3
962	Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study. 2020 , 158, 562-569	15
961	Characterization of multicellular breast tumor spheroids using image data-driven biophysical mathematical modeling. 2020 , 10, 11583	6
960	A Review of T-Cell Related Therapy for Osteosarcoma. 2020 , 21,	6
959	Melanoma brain metastases - Interdisciplinary management recommendations 2020. 2020 , 89, 102083	25
958	Scientific diligence for oncology drugs: a pharmacology, translational medicine and clinical perspective. 2020 , 25, 1855-1864	

957	Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors. 2020 , 9, 1776058	12
956	Immunotherapy as sensitizer for local radiotherapy. 2020 , 9, 1832760	10
955	Molecular imaging in immuno-oncology: current status and translational perspectives. 2020 , 20, 1199-1211	1
954	Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. 2020 , 9, 2059-2073	6
953	Antitumor activity without on-target off-tumor toxicity of GD2-chimeric antigen receptor T cells in patients with neuroblastoma. 2020 , 12,	37
952	Immunotherapy Moves to the Early-Stage Setting in Non-Small Cell Lung Cancer: Emerging Evidence and the Role of Biomarkers. 2020 , 12,	6
951	Sintilimab: A Promising Anti-Tumor PD-1 Antibody. 2020 , 10, 594558	30
950	Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect. 2020 , 10, 566315	12
949	Overcoming Immune Evasion in Melanoma. 2020 , 21,	29
948	Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. 2020 , 12,	13
947	Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma. 2020 , 2020, 9350272	4
946	Clinical Challenges of Immune Checkpoint Inhibitors. 2020 , 38, 326-333	83
945	Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclave a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients. 2020 , 148, 1-11	25
944	Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer. 2020 , 40, 1412-1430	6
943	Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: Clarity Amidst Rapid Evolution. 2020 , 297, 97-98	2
942	Complete response to immune checkpoint inhibitors-based therapy in advanced renal cell carcinoma patients. A meta-analysis of randomized clinical trials. 2020 , 38, 798.e17-798.e24	4
941	Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. 2020 , 297, 87-96	22
940	AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer. 2020 , 20, 683	26

939	Understanding Response to Immunotherapy Using Standard of Care and Experimental Imaging Approaches. 2020 , 108, 242-257	2
938	Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives. 2020 , 123, 885-897	15
937	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. 2020 , 21, 69	10
936	Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature. 2020 , 7, 366	3
935	Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. 2020 , 5,	7
934	[Monitoring of immunotherapy : Possibilities and limitations]. 2020 , 60, 711-720	
933	A decade of immune-checkpoint inhibitors in cancer therapy. 2020 , 11, 3801	289
932	Is there a link between very early changes of primary and secondary lymphoid organs in F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy?. 2020 , 8,	7
931	Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. 2020 , 44, 619-626	4
930	Atypical patterns of response and progression in the era of immunotherapy combinations. 2020 , 16, 1707-1713	7
929	Impact of ultra-low dose CT acquisition on semi-automated RECIST tool in the evaluation of malignant focal liver lesions. 2020 , 101, 473-479	3
928	Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial. 2020 , 38, 3129-3137	30
927	Tumour Biology Characterisation by Imaging in Clinic. 2020 , 325-360	
926	Radiomics and "radi-omics" in cancer immunotherapy: a guide for clinicians. 2020 , 154, 103068	7
925	Atypical response patterns in metastatic melanoma and renal cell carcinoma patients treated with nivolumab: A single center experience. 2021 , 27, 1106-1111	0
924	Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. 2020 , 12,	20
923	Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies. 2020 , 9,	3
922	Increased SNX20 and PD-L1 Levels Can Predict the Clinical Response to PD-1 Inhibitors in Lung Adenocarcinoma. 2020 , 13, 10075-10085	3

921	Impact of PET/CT for Assessing Response to Immunotherapy-A Clinical Perspective. 2020 , 9,		13
920	Addition of Radiotherapy to Immunotherapy: Effects on Outcome of Different Subgroups Using a Propensity Score Matching. 2020 , 12,		1
919	Cancer-Specific Immune Prognostic Signature in Solid Tumors and Its Relation to Immune Checkpoint Therapies. 2020 , 12,		8
918	Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary study. 2020 , 9, 8355-8363		5
917	Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. 2020 , 8,		18
916	Functional Imaging of Immunotherapy: Response Criteria, Imaging Characteristics, and Novel Immunoimaging of Advanced Malignancies. 2020 , 8, 1		
915	Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report. 2020 , 31, 866-871		4
914	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. 2020 , 31, 1233-1241		4
913	HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis. 2020 , 9,		17
912	Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy. 2020 , 22, 116		5
911	Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. 2020 , 146, 3269-3279		9
910	Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. <i>Lancet Oncology, The</i> , 2020 , 21, 1213-1223	21.7	53
909	Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. 2020 , 10, 10838-10848		18
908	Phase I Oncology Drug Development. 2020 ,		
907	A New Prognostic Index Combines the Metabolic Response and RECIST 1.1 to Evaluate the Therapeutic Response in Patients With Non-Small Cell Lung Cancer. 2020 , 10, 1503		0
906	Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis. 2020 , 3, e2011809		8
905	Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy. 2020 , 22, 109		4
904	Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). 2020 , 26, 5621-5630		9

903	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. 2020 , 108, 70-80	2
902	Immunotherapy in Corticotroph and Lactotroph Aggressive Tumors and Carcinomas: Two Case Reports and a Review of the Literature. 2020 , 10,	17
901	Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure. 2020 , 12,	11
900	Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors. 2020 , 8,	11
899	Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers. 2021 , 19, 274.e1-274.e16	2
898	Equivocal evaluation of progressive disease in patients treated with immune checkpoint inhibitors: a challenge for clinical trials and biomarker research. 2020 , 1-4	
897	Opioids impair Nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer. 2020 ,	1
896	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. 2020 , 12, CD013257	12
895	Moderne Aspekte der Immuntherapie mit Checkpoint-Inhibitoren bei Melanom. 2020 , 8, 92-101	
894	RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study. 2020 , 8,	10
893	PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice. 2020 , 26, 4186-4197	18
892	Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. 2020 , 6, eaay6298	16
891	The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy. 2020 , 19, 81	34
890	Imaging Technologies to Monitor the Immune System. 2020 , 11, 1067	21
889	Renal Cell Carcinoma: The Evolving Role of Imaging in the 21st Century. 2020 , 41, 344-350	3
888	Current Panorama and Challenges for Neoadjuvant Cancer Immunotherapy. 2020 , 26, 5068-5077	18
887	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. 2020 , 86, 1736-1752	5
886	Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis. 2020 , 8,	26

885	Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. 2020 , 8,	34
884	Pseudoprogession and Hyperprogression as New Forms of Response to Immunotherapy. 2020 , 34, 463-476	23
883	[Immunotherapy in head and neck squamous cell carcinoma : Abscopal effects in combination with radiotherapy, extraordinary responses in combination with chemotherapy, and pseudoprogession]. 2020 , 61, 682-689	
882	Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer: A case report. 2020 , 99, e19790	6
881	Acquired Resistance to Immune Checkpoint Blockade Therapies. 2020 , 12,	3
880	Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. 2020 , 9, 1751548	12
879	Early Assessment of Molecular Progression and Response by Whole-genome Circulating Tumor DNA in Advanced Solid Tumors. 2020 , 19, 1486-1496	10
878	ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. 2020 , 27, 3498-3499	
877	Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters. 2020 , 12,	12
876	Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer. 2020 , 12, 3547-3560	5
875	A review of cancer immunotherapy: from the past, to the present, to the future. 2020 , 27, S87-S97	182
874	The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. 2020 , 56, 380-389	
873	Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis. 2020 , 153, 102984	17
872	Single-Arm Clinical Trials as Pivotal Evidence for Cancer Drug Approval: A Retrospective Cohort Study of Centralized European Marketing Authorizations Between 2010 and 2019. 2020 , 108, 653-660	5
871	Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review. 2020 , 12, 1758835920922028	17
870	Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. 2020 , 158, 303-308	0
869	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. 2020 , 20, 557	19
868	C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma. 2020 , 86, 75-85	2

867	Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. 2020 , 38, 2667-2676	18
866	Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma. 2020 , 11, 1127	6
865	Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade. 2020 , 8,	16
864	INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies. 2020 , 20, 523	11
863	Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer. 2020 , 146, 2979-2988	3
862	Evaluation of liver tumour response by imaging. 2020 , 2, 100100	14
861	Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. 2020 , 9, 4907-4917	2
860	Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. 2020 , 69, 2513-2522	12
859	Pseudoprogression or unexpected favorable response to third-line therapy: a challenging metastatic bladder cancer case. 2020 , 5, e58	
858	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. 2020 , 34, 83-91	2
857	Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. 2020 , 11, 1068-1075	10
856	Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study. 2020 , 129, 97-106	24
855	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. 2020 , 11, 492	21
854	Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study. 2020 , 59, 733-740	4
853	Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors. 2020 , 20, 207	12
852	Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. 2020 , 38, 2981-2992	174
851	Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma. 2020 , 12, 1758835920929583	
850	Immunotherapy For Ovarian Cancer: Recent Advances And Combination Therapeutic Approaches. 2020 , 13, 6109-6129	25

849	Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of F-FDG PET/CT. 2020 , 21, 485-497	4
848	Prolonged efficacy of pembrolizumab in a patient presenting a multi-treated metastatic hepatocolangiocarcinoma. 2020 , 13, 1756284820935189	4
847	Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: A case report and review of the literature. 2020 , 146, 335-340	5
846	Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm. 2020 , 17, 707-715	28
845	MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy. 2020 , 8,	10
844	Opportunities for Quantitative Translational Modeling in Oncology. 2020 , 108, 447-457	4
843	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). 2020 , 26, 2461-2465	2
842	Managing Hyperprogressive Disease in the Era of Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade: A Case Discussion and Review of the Literature. 2020 , 25, 369-374	7
841	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. 2020 , 9, 2643-2652	14
840	Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics. 2020 , 10, 3565	17
839	Assessing Treatment Benefit in Immuno-oncology. 2020 , 12, 83-103	4
838	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. 2020 , 31, 334-351	64
837	The role of molecular and imaging biomarkers in the evaluation of inflammation in oncology. 2020 , 35, 5-7	
836	Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors. 2020 , 45, 187-194	17
835	Immunotherapy-related adverse effects on F-FDG PET/CT imaging. 2020 , 93, 20190832	17
834	A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226. 2020 , 143, 1-11	14
833	Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?. 2020 , 25, 94-98	26
832	Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications. 2020 , 12,	26

831	The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors. 2020 , 146, 1235-1243	23
830	Impact of Baseline Nutrition and Exercise Status on Toxicity and Outcomes in Phase I and II Oncology Clinical Trial Participants. 2020 , 25, 161-169	10
829	The need of a clinically oriented reporting of 18F-FDG PET/CT in non-small cell lung cancer (NSCLC). 2020 , 8, 29-38	
828	Immune checkpoint inhibitors in advanced non-small cell lung cancer: A metacentric experience from India. 2020 , 44, 100549	2
827	mRECIST for HCC: Performance and novel refinements. 2020 , 72, 288-306	86
826	Criteria of metabolic response to immunotherapy. 2020 , 39, 51-56	
825	TCR Repertoire Diversity of Peripheral PD-1CD8 T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. 2020 , 8, 146-154	72
824	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review. 2020 , 12,	17
823	Intérêt pronostique et prédictif de la TEP-TDM au 18F-FDG au bilan initial des mélanomes de stade IIIB-C-D et IV avant traitement par anti-PD-1. 2020 , 44, 65-71	
822	Radiological Monitoring of Modern Immunotherapy: A Novel Challenge for Interdisciplinary Patient Care. 2020 , 192, 235-245	2
821	Molecular markers related to immunosurveillance as predictive and monitoring tools in non-small cell lung cancer: recent accomplishments and future promises. 2020 , 20, 335-344	6
820	Top 10 Challenges in Cancer Immunotherapy. 2020 , 52, 17-35	460
819	Tumor Immunology and Tumor Evolution: Intertwined Histories. 2020 , 52, 55-81	179
818	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy. 2020 , 26, 61-70	14
817	Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. 2020 , 6, 872-880	58
816	A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer. 2020 , 6, 888-894	122
815	Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. 2020 , 4,	5
814	Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. 2020 , 26, 3578-3588	36

813	Immuntherapeutische Therapieansätze in Überblick. 2020 , 53, 216-223	
812	Imaging and clinical correlates with regorafenib in metastatic colorectal cancer. 2020 , 86, 102020	4
811	Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce. 2020 , 8,	43
810	Master protocols in immuno-oncology: do novel drugs deserve novel designs?. 2020 , 8,	6
809	Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis. 2020 , 11,	8
808	Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer. 2020 , 17,	12
807	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. 2020 , 8,	4
806	Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. 2020 , 15, e0231038	2
805	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. 2020 , 47, 2227-2232	4
804	Imaging response assessment following stereotactic body radiotherapy for solid tumour metastases of the spine: Current challenges and future directions. 2020 , 64, 385-397	1
803	How Non-invasive Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. 2020 , 11, 154	18
802	Immunotherapy. 2020 ,	1
801	Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. 2020 , 47, 2787-2795	12
800	Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. 2020 , 143, 47-54	0
799	Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy. 2020 , 62, 131-138	1
798	Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. 2020 , 157, 578-584	11
797	Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients. 2020 , 122, 1782-1790	3
796	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. 2020 , 87, E281-E288	6

795	Predictive value of FDG-PET imaging for relapse in metastatic melanoma patients treated with immunotherapy. 2020 , 34, 2261-2267	4
794	Identification of Non-Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. 2020 , 26, 2151-2162	40
793	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. 2020 , 26, 4414-4425	30
792	Hyperprogression Under Immune Checkpoint-Based Immunotherapy-Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model. 2020 , 12,	10
791	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. 2020 , 21,	20
790	Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. 2021 , 73 Suppl 1, 158-191	63
789	Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting. 2021 , 35, 105-115	2
788	A multidisciplinary consensus on the morphological and functional responses to immunotherapy treatment. 2021 , 23, 434-449	1
787	Automation of data analysis in molecular cancer imaging and its potential impact on future clinical practice. 2021 , 188, 30-36	4
786	Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers - a retrospective study of a single institution. 2021 , 70, 1393-1403	11
785	Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). 2021 , 14, 277-287	3
784	The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors. 2021 , 22, e57-e62	14
783	Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. 2021 , 22, e379-e389	4
782	A high number of PD-L1 CD14 monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. 2021 , 70, 337-348	5
781	Fundamentals of Cancer Immunology and Their Application to Cancer Vaccines. 2021 , 14, 120-131	1
780	TGFβ biology in cancer progression and immunotherapy. 2021 , 18, 9-34	135
779	Patterns of progression in patients treated for immuno-oncology antibodies combination. 2021 , 70, 221-232	7
778	Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer. 2021 , 23, 582-590	1

777	Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab. 2021 , 127, 90-95	2
776	Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. 2021 , 31, 1853-1862	5
775	Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. 2021 , 137, 1669-1678	44
774	Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. 2021 , 27, 1019-1028	14
773	Clarification of Definitions of Hyperprogressive Disease During Immunotherapy-Reply. 2021 , 7, 137	1
772	Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?. 2021 , 149, 31-41	6
771	Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism. 2021 , 41, 120-143	12
770	MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer. 2021 , 40, 833-847	17
769	PET/CT and PET/MR in Melanoma and Sarcoma. 2021 ,	
768	Hyperprogressive disease in patients receiving immune checkpoint inhibitors. 2021 , 45, 100688	2
767	Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. 2021 , 144, 9-16	15
766	iRECIST pour les nuls. 2021 , 4, 18-21	
765	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. 2021 , 371, 602-609	239
764	Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. 2021 , 149, 277-286	2
763	Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma. 2021 , 56, 1134-1143	6
762	Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial. 2021 , 143, 55-63	13
761	MR cell size imaging with temporal diffusion spectroscopy. 2021 , 77, 109-123	3
760	Cost-effectiveness of nivolumab in advanced melanoma: a drug review. 2021 , 21, 13-28	

759	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials. 2021 , 61, 810-819	4
758	Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. 2021 , 27, 402-407	5
757	CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies. 2021 , 46, 2219-2235	3
756	The impact of BRAF mutation status on clinical outcomes with anti-PD-1 monotherapy versus combination ipilimumab/nivolumab in treatment-naïve advanced stage melanoma. 2021 , 34, 629-640	1
755	Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab. 2021 , 70, 657-665	7
754	Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. 2021 , 70, 1491-1496	5
753	Intratumoral Immunotherapy: From Trial Design to Clinical Practice. 2021 , 27, 665-679	19
752	Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. 2021 , 23, 139-147	1
751	Manual of Normative Measurements in Head and Neck Imaging. 2021 ,	
750	Évaluation de la réponse pathologique après thérapie néoadjuvante dans les cancers pulmonaires. 2021 , 2021, 43-48	
749	Comparison of CT Volumetry and RECIST to Predict the Treatment Response and Overall Survival in Gastric Cancer Liver Metastases. 2021 , 82, 876	
748	Treatment Response Evaluation: Science and Practice. 2021 , 3-9	
747	Ipilimumab in Melanoma: An Evergreen Drug. 2021 , 217-235	
746	Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. 2021 , 28, 1499-1510	1
745	Clinical challenges in neoadjuvant immunotherapy for non-small cell lung cancer. 2021 , 33, 203-215	1
744	Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model. 2021 , 13, 1758835920984061	4
743	The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy. 2021 , 21, 19	7
742	Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies. 2021 , 53, 762-769	3

741	MRI and Diffusion-Weighted MRI in Treatment Response Evaluation Overview. 2021 , 17-26	
740	PET and PET-CT in Treatment Response Evaluation: Overview. 2021 , 27-35	
739	18F-FDG PET-CT in Treatment Response Evaluation in Cutaneous Malignant Melanoma. 2021 , 377-394	
738	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. 2021 , 83-99	
737	Checkpoint-Inhibitoren. 2021 , 1-11	
736	CT in Treatment Response Assessment in Oncology. 2021 , 11-16	
735	Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC). 2021 , 13,	8
734	Impact of Dose-Effect in Smoking on the Effectiveness of Pembrolizumab in Patients with Metastatic Urothelial Carcinoma. 2021 , 16, 189-196	1
733	Prediction of the Therapeutic Effects of Pembrolizumab and Nivolumab in Advanced Non-Small Cell Lung Cancer by Platelet-Derived Microparticles in Circulating Blood. 2021 , 20, 1533033821997817	3
732	Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors. 2021 , 9,	16
731	Are radiologists ready to evaluate true response to immunotherapy?. 2021 , 12, 29	2
730	A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer. 2021 , 11, 544339	6
729	First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. 2021 , 112, 1514-1523	6
728	Lights and Shadows in Immuno-Oncology Drug Development. 2021 , 13,	
727	Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. 2021 , 73, 232-239	1
726	Dynamic monitoring of serum specific tumor markers predicts the response to PD-1 blockade and prognosis of patients with malignant tumors.. 2021 , 10, 779-789	2
725	A narrative review: depth of response as a predictor of the long-term outcomes for solid tumors.. 2021 , 10, 1119-1130	0
724	Two cases of rare late onset life-threatening pseudoprogression with immune check point inhibitors in advanced cancer patients - a case report. 2021 , 60, 683-686	

723	Examining the Relationship between Circulating CD4- CD8- Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy-Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma. 2021 , 10,	0
722	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. 2021 , 18, 435-453	9
721	Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors. 2021 , 152, 109-118	2
720	Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials. 2021 , 4, e2036741	1
719	Dissociated response and clinical benefit in patients treated with nivolumab monotherapy. 2021 , 39, 1170-1178	4
718	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. 2021 , 135, 109484	9
717	Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. 2021 , 9,	25
716	expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. 2021 , 21, 397	1
715	Introducing the Node Reporting and Data System 1.0 (Node-RADS): a concept for standardized assessment of lymph nodes in cancer. 2021 , 31, 6116-6124	7
714	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. 2021 , 26, 558-e1098	7
713	Potential of circulating tumor DNA as a predictor of therapeutic responses to immune checkpoint blockades in metastatic renal cell carcinoma. 2021 , 11, 5600	0
712	Tumor Response Dynamics During First-Line Pembrolizumab Therapy in Patients With Advanced Non-Small-Cell Lung Cancer. 2021 , 5,	1
711	Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial. 2021 , 21, 323	5
710	Immunotherapy, cancer and PET. 2021 , 40, 123-135	
709	Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients. 2021 , 9,	4
708	PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC-current state and future directions. 2021 , 48, 3975-3989	6
707	Apport de la TEP-TDM au 18F-FDG chez des patients avec cancer bronchique non ^ petites cellules ou mlanome mfastatique traité par immunothrapie. 2021 , 45, 59-69	
706	Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer. 2021 , 11, 642883	4

705	CT based radiomic approach on first line pembrolizumab in lung cancer. 2021 , 11, 6633	9
704	Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?. 2021 , 94, 102157	1
703	PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. 2021 , 11, 3120-3133	6
702	Response to Immune Checkpoint Inhibitor Therapy in Patients with Unresectable Recurrent Malignant Pleural Mesothelioma Shown by FDG-PET and CT. 2021 , 13,	1
701	Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. 2021 , 10,	5
700	The role of opioids in cancer response to immunotherapy. 2021 , 19, 119	4
699	Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for NSCLC. 2021 , 4, e1368	2
698	Structural and functional radiomics for lung cancer. 2021 , 48, 3961-3974	7
697	Immunotherapy, cancer and PET. 2021 , 40, 123-135	
696	Radiomics in immuno-oncology. 2021 , 9, 100028	0
695	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. 2021 , 12, 1402	16
694	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. 2021 , 11, 657615	10
693	Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview. 2021 , 11,	7
692	Role of surgery in a novel multimodal therapeutic approach to complete cure of advanced lung cancer: current and future perspectives. 2021 , 1	1
691	Radiomics in Renal Cell Carcinoma-A Systematic Review and Meta-Analysis. 2021 , 13,	3
690	Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri. 2021 , 13,	3
689	Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. 2021 , 9,	0
688	A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. 2021 , 299, 109-119	14

687	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. 2021 , 26,	11
686	Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review. 2021 , 21, 425	4
685	Germline variants that influence the tumor immune microenvironment also drive response to immunotherapy.	
684	Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. 2021 , 106, e3704-e3713	19
683	Imaging spectrum of adverse events of immune checkpoint inhibitors. 2021 , 76, 262-272	2
682	Delayed Response After Confirmed Progression (DR) and Other Unique Immunotherapy-Related Treatment Concepts in Cutaneous Squamous Cell Carcinoma. 2021 , 11, 656611	2
681	Development of a Prognostic AI-Monitor for Metastatic Urothelial Cancer Patients Receiving Immunotherapy. 2021 , 11, 637804	2
680	Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. 2021 , 11, 657639	7
679	Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. 2021 , 9,	9
678	Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask. 2021 , 216, 1099-1111	1
677	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. 2021 , 76, 247-261	
676	Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. 2021 , 4, CD013257	8
675	The Next Decade of Immune Checkpoint Therapy. 2021 , 11, 838-857	76
674	Pre-Immunotherapy Contrast-Enhanced CT Texture-Based Classification: A Useful Approach to Non-Small Cell Lung Cancer Immunotherapy Efficacy Prediction. 2021 , 11, 591106	0
673	Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study. 2021 , 10, 1819-1828	2
672	Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework. 2021 , 125, 155-163	5
671	Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma. 2021 , 45, 100736	1
670	Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer. 2021 , 161, 211-220	7

669	Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. 2021 , 21, 514	1
668	Transformational Role of Medical Imaging in (Radiation) Oncology. 2021 , 13,	2
667	Immunotherapy for non-small cell lung cancer in the elderly population: a generic protocol.	
666	Results of Dynamic Contrast-Enhanced Ultrasound Correlate With Treatment Outcome in Canine Neoplasia Treated With Electrochemotherapy and Interleukin-12 Plasmid Electrotransfer. 2021 , 8, 679073	1
665	Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy. 2021 , 12, 323-334	3
664	PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy. 2021 , 34, 1719-1727	10
663	Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review. 2021 , 11, 640447	1
662	Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial. 2021 , 148, 382-394	5
661	Immunotherapy for pancreatic cancer. 2021 , 9, 2969-2982	2
660	The Incorporation of Immunotherapy and Targeted Therapy Into Chemoradiation for Cervical Cancer: A Focused Review. 2021 , 11, 663749	2
659	Imaging of treatment response during systemic therapy for hepatocellular carcinoma. 2021 , 46, 3625-3633	1
658	Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis. 2021 , 11, 696716	2
657	Tumor burden as possible biomarker of outcome in advanced NSCLC patients treated with immunotherapy: a single center, retrospective, real-world analysis.	0
656	Incidence of Immune-Mediated Pseudoprogression of Lymphoma Treated with Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis. 2021 , 10,	2
655	Pearls and Pitfalls in the Imaging of Targeted Therapy and Immunotherapy in Lung Cancer.. 2021 , 42, 552-562	
654	Current Status and Prospects of Immunotherapy for Gynecologic Melanoma. 2021 , 11,	0
653	CDISC-compliant clinical trial imaging management system with automatic verification and data Transformation: Focusing on tumor response assessment data in clinical trials. 2021 , 117, 103782	1
652	Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. 2021 , 16, e0252665	1

651	A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. 2021 , 10, 500-509	0
650	Clinical benefit of continuing pembrolizumab treatment beyond progression in patients with metastatic urothelial carcinoma. 2021 , 1	1
649	Post-immunotherapy imaging in lung cancer. 2021 ,	1
648	Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. 2021 , 13,	3
647	Drug Development in Tissue-Agnostic Indications. 2021 , 13,	2
646	Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. 2021 , 41, 2985-2992	0
645	Imaging Assessment of Tumor Response in the Era of Immunotherapy. 2021 , 11,	1
644	Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade. 2021 , 11, 684110	3
643	The dark side of immunotherapy. 2021 , 9, 1041	2
642	Letter to the Editor from Colle. 2021 , 9,	0
641	Guidelines for clinical evaluation of anti-cancer drugs. 2021 , 112, 2563-2577	5
640	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. 2021 , 6, 100117	11
639	Endpoints in clinical trials for liver cancer and their value in evidence-based clinical decision making: An unresolved Gordian knot. 2021 , 74, 1483-1488	9
638	Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. 2021 , 9,	13
637	The Role of the Immune Metabolic Prognostic Index in Patients with Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression during Treatment with Nivolumab. 2021 , 13,	5
636	Differences in treatment effect size between progression-free survival and overall survival in anti-PD-1/PD-L1 inhibitors-based trials in advanced NSCLC: a systematic review and meta-analysis. 2021 , 10, 2562-2572	
635	Author response to Colle. 2021 , 9,	
634	Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers. 2021 , 9, e00808	2

633	Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma. 2021 , 11, 628324	0
632	Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy. 2021 ,	1
631	Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy. 2021 , 48, 4369-4376	4
630	How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. 2021 , 10, 3486-3502	1
629	Imaging biomarkers for evaluating tumor response: RECIST and beyond. 2021 , 9, 52	10
628	A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors. 2021 , 39, 1624-1632	
627	Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. 2021 , 16, e0252041	1
626	Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology, The</i> , 2021 , 22, 946-958	21.7 23
625	Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score \geq 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study. 2021 , 39, 2327-2338	53
624	Updated Trends in Imaging Practices for Pancreatic Neuroendocrine Tumors (PNETs): A Systematic Review and Meta-Analysis to Pave the Way for Standardization in the New Era of Big Data and Artificial Intelligence. 2021 , 11, 628408	2
623	A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer. 2021 , 22, 268-273	0
622	Hyperprogression under immunotherapy: a new form of immunotherapy response?-a narrative literature review. 2021 , 10, 3276-3291	4
621	Prognostic value of DCE-CT-derived blood volume and flow compared to core biopsy microvessel density in patients with metastatic renal cell carcinoma. 2021 , 5, 32	1
620	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. 2021 , 12, 678409	4
619	Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. 2021 , 13,	0
618	Predictive value of 3'-deoxy-3'-F-fluorothymidine PET in the early response to anti-programmed death-1 therapy in patients with advanced non-small cell lung cancer. 2021 , 9,	1
617	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. 2021 , 11,	6
616	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. 2021 , 41, 747-795	36

615	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. 2021 , 1	1
614	Non-invasive diagnosis and follow-up of primary malignant liver tumours. 2021 , 46, 101766	
613	Radiomics in the Setting of Neoadjuvant Radiotherapy: A New Approach for Tailored Treatment. 2021 , 13,	9
612	Comparison of Methods for Analyzing Radiological Response of Colorectal Cancer Liver Metastasis After Neoadjuvant Chemotherapeutic Treatment. 2021 , 18,	
611	Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. 2021 , 11, 6930	1
610	Local ablative therapies in oligometastatic NSCLC-upfront or outback?-a narrative review. 2021 , 10, 3446-3456	1
609	Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan. 2021 , 13,	1
608	Two centres experience of lung cancer resection in patients with advanced non-small cell lung cancer upon treatment with immune checkpoint inhibitors: safety and clinical outcomes. 2021 , 60, 1297-1305	3
607	Tumor Response End Points as Surrogates for Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-Analysis. 2021 , 5,	3
606	Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health. 2021 , 26, e1786-e1799	11
605	Clinical evidence for a biological effect of epigenetically active decitabine in relapsed or progressive rhabdoid tumors. 2021 , 68, e29267	0
604	Volume increase of spleen in melanoma patients undergoing immune checkpoint blockade. 2021 , 13, 885-891	1
603	Advances in immune therapies for the treatment of microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer (Review). 2021 , 59,	
602	Intraspecies strain exclusion, antibiotic pretreatment, and donor selection control microbiota engraftment after fecal transplantation.	2
601	Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. 2021 , 16, e0255798	1
600	Development and Validation of a Nomogram for Predicting Prognosis to Immune Checkpoint Inhibitors Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer. 2021 , 11, 685047	
599	Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma. 2021 , 37, 100840	0
598	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. 2021 , 9,	7

597	Detection and viability of murine NK cells in vivo in a lymphoma model using fluorine-19 MRI. 2021 , 34, e4600	0
596	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. 2021 , 13,	5
595	Preliminary Safety and Potential Effect of 6B11-OCIK Adoptive Cell Therapy Against Platinum-Resistant Recurrent or Refractory Ovarian Cancer. 2021 , 12, 707468	0
594	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. 2021 , 12, 5045	6
593	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. 2021 , 2, 100208	
592	RECIST 1.1, Choi and mChoi criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with Regorafenib and anti-PD-1 antibody. 2021 , 141, 109823	2
591	Incidence, risk factors and clinical outcome of venous thromboembolism in non-small cell lung cancer patients receiving immune checkpoint inhibition. 2021 , 4, 100056	1
590	Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma. 2021 , 1	4
589	KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma. 2021 , 17, 2847-2855	4
588	Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles. 2021 , 21, 939	0
587	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. 2021 , 13,	0
586	Serum levels of VCAM-1 are associated with survival in patients treated with nivolumab for NSCLC. 2021 , e13668	1
585	First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥ 0 . 2021 , 17, 3007-3016	4
584	Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma. 2021 , 11, 718589	2
583	Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. 2021 ,	27
582	Non-Invasive Ultrasonic Description of Tumor Evolution. 2021 , 13,	
581	Hypothyroidism is a predictive factor of superior antitumour efficacy of programmed death 1 inhibitors in hepatocellular carcinoma. 2022 , 150, 472-481	1
580	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. 2021 , 12, 5668	7

579	Assessment of early metabolic progression in melanoma patients under immunotherapy: an F-FDG PET/CT study. 2021 , 11, 89	4
578	Complete response and renal cell carcinoma in the immunotherapy era: The paradox of good news. 2021 , 99, 102239	5
577	Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors. 2021 , 94, 20210228	0
576	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. 2021 , 13,	0
575	A CTL/M2 macrophage-related four-gene signature predicting metastasis-free survival in triple-negative breast cancer treated with adjuvant radiotherapy. 2021 , 190, 329-341	0
574	Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study. 2021 , 205, 29-39	7
573	Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy. 2021 , 159, 45-55	4
572	Sintilimab plus IBI305 for hepatocellular carcinoma. <i>Lancet Oncology, The</i> , 2021 , 22, e387	21.7
571	Update on Molecular Imaging and Precision Medicine in Lung Cancer. 2021 , 59, 693-703	3
570	Immune PET Imaging. 2021 , 59, 875-886	0
569	Precision Nuclear Medicine: The Evolving Role of PET in Melanoma. 2021 , 59, 755-772	2
568	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLC-Real World Efficacy. 2021 , 13,	1
567	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. 2021 , 162, 60-67	11
566	Real-world experience with anti-PD-1/PD-L1 monotherapy in patients with non-small cell lung cancer : A retrospective Austrian multicenter study. 2021 , 133, 1122-1130	1
565	In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome.	
564	Imaging CAR T-cell kinetics in solid tumors: Translational implications. 2021 , 22, 355-367	2
563	Radiomics as a New Frontier of Imaging for Cancer Prognosis: A Narrative Review. 2021 , 11,	6
562	Update on the Role of Imaging in Clinical Staging and Restaging of Renal Cell Carcinoma Based on the AJCC 8th Edition, From the Special Series on Cancer Staging. 2021 , 217, 541-555	1

561	Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy. 2021 , 21, 399-406	2
560	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. 2021 , 26,	3
559	Sintilimab plus IBI305 for hepatocellular carcinoma - Author's reply. <i>Lancet Oncology, The</i> , 2021 , 22, e388-1.7	1.7
558	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. 2021 , 41, 1387-1407	3
557	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. 2021 , 166, 103460	2
556	Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy. 2021 , 160, 50-58	2
555	Systemic treatment of hepatocellular carcinoma: An EASL position paper. 2021 , 75, 960-974	49
554	Outcomes of patients with cancer and sarcoid-like granulomatosis associated with immune checkpoint inhibitors: A case-control study. 2021 , 156, 46-59	2
553	Tumor Metrics Standardization and Integration with Electronic Health Records: A Step Forward on a Long Road. 2021 , 28, 1408-1409	0
552	Immunotherapy for Head and Neck Cancer. 2021 , 35, 1021-1037	3
551	First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors. 2021 ,	2
550	PET/MRI Improves Management of Children with Cancer. 2021 , 62, 1334-1340	2
549	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. 2021 , 161, 60-67	
548	Progress and challenges of immunotherapy in triple-negative breast cancer. 2021 , 1876, 188593	14
547	Image-guided cancer immunotherapy. 2022 , 427-467	
546	Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer. 2021 , 46, 1787-1791	
545	A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect. 2021 , 20, 528-550	0
544	Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy. 2021 , 22, 366-375	4

543	Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images. 2021 , 11, 2098-2107	17
542	Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. 2021 , 13,	7
541	Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer. 2021 , 11, 4155-4170	12
540	Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. 2021 , 22, 1310-1322	1
539	Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma. 2021 , 10, 1562-1575	6
538	Combining regulatory and exploratory trials. 2021 , 251-255	
537	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. 2021 , 13,	2
536	PD-1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma. 2021 , 4, e1327	2
535	Hyperprogression: A novel response pattern under immunotherapy. 2020 , 10, e167	11
534	Dynamic Treatment Stratification Using ctDNA. 2020 , 215, 263-273	8
533	Cancer Imaging in Immunotherapy. 2020 , 1244, 309-324	2
532	A comparison between the assessments of progression-free survival by local investigators versus blinded independent central reviews in phase III oncology trials. 2020 , 76, 1083-1092	5
531	The efficiency of F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer. 2020 , 47, 1209-1219	23
530	Interim [F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. 2021 , 48, 1932-1943	9
529	F-PSMA-1007 PET/CT for response assessment in patients with metastatic renal cell carcinoma undergoing tyrosine kinase or checkpoint inhibitor therapy: preliminary results. 2021 , 48, 2031-2037	5
528	Particular findings on lung CT in patients undergoing immunotherapy for bronchogenic carcinoma. 2020 , 132, 467-474	5
527	The Importance of Imaging Studies in the Assessment of Response to Immunotherapy in Lung Cancer. 2020 , 56, 380-389	2
526	Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy. 2020 , 62, 131-138	3

525	The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. 2019 , 16, 442-458	59
524	Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. 2021 , 21, 501-510	3
523	PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. 2020 , 9, 1711-1650	18
522	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. 2021 , 25, 146-151	6
521	Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer.	1
520	A circulating T-cell differentiation marker to predict response to immune checkpoint inhibitors.	2
519	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. 2017 , 37, 2132-2144	68
518	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). 2020 , 9, 682-720	108
517	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. 2020 , 10, 143	8
516	Imaging of tumour response to immunotherapy. 2020 , 4, 2	42
515	PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions. 2020 , 4, 63	18
514	The combination of immunotherapy and radiation therapy for non-small cell lung cancer. 2018 , 7, 90	1
513	QIN Benchmarks for Clinical Translation of Quantitative Imaging Tools. 2019 , 5, 1-6	8
512	Repeatability and Reproducibility of ADC Histogram Metrics from the ACRIN 6698 Breast Cancer Therapy Response Trial. 2020 , 6, 177-185	7
511	Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy. 2018 , 9, 25265-25276	33
510	Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. 2018 , 9, 34520-34527	31
509	Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. 2019 , 10, 2012-2021	2
508	Role of imaging in management of hepatocellular carcinoma: surveillance, diagnosis, and treatment response. 2020 , 6,	7

507	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. 2019 , 16, 655-670	39
506	Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?. 2018 , 6, 222	12
505	Surrogate study endpoints in the era of cancer immunotherapy. 2018 , 6, S27	12
504	The role of endobronchial ultrasound transbronchial needle aspiration for programmed death ligand 1 testing and next generation sequencing in advanced non-small cell lung cancer. 2019 , 7, 351	10
503	Challenges of evaluating immunotherapy efficacy in solid tumors. 2019 , 31, 853-861	3
502	Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population. 2020 , 13, 867-876	7
501	Pseudoprogression in patients on immunotherapy. 2019 , 10-14	2
500	Outcome Prediction and Evaluation by Imaging the Key Elements of Therapeutic Responses to Cancer Immunotherapies Using PET. 2020 , 26, 675-687	2
499	PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay. 2020 , 21, 1664-1671	3
498	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. 2020 , 13, 24-31	2
497	Unlocking the Power of Artificial Intelligence and Big Data in Medicine. 2019 , 21, e16607	21
496	Update on tumor metabolism and patterns of response to immunotherapy. 2020 , 64, 175-185	5
495	Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab. 2019 , 90, 468-474	2
494	Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab - real-world experience. 2020 , 54, 119-127	3
493	[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. 2020 , 54, 285-294	20
492	Practical consensus recommendations - Current role of immune response evaluation criteria in solid tumors criteria in the management of cancer patients receiving immunotherapy. 4, 21-23	1
491	Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of F-FDG PET/CT. 2020 , 61, 943-950	20
490	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 20, 1042-1113	96

489	Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. 2020 , 26, 328-339	19
488	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. 2020 , 12,	3
487	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. 2020 , 13,	3
486	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. 2020 , 13,	3
485	[Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)]. 2020 , 23, 65-76	8
484	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. 2020 , 28, 119-130	5
483	Should We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?. 2019 , 2, 36-39	2
482	Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy. 2020 , 52, 730-738	4
481	2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2019 , 13, 227-299	151
480	Immune checkpoint inhibitors in patients with pretreated Hodgkin's lymphoma: a Korean single-center, retrospective study. 2020 , 55, 85-90	2
479	Objective response rate assessment in oncology: Current situation and future expectations. 2020 , 11, 53-73	16
478	Pseudoprogression and Immunotherapy Phenomena. 2020 , 11, 723-731	1
477	Quantitative Imaging Assessment for Clinical Trials in Oncology. 2019 , 17, 1505-1511	3
476	Clinical Trials and Methodology of Cancer Research. 2021 , 259-267	
475	Immunotherapy: From Discovery to Bedside. 2021 , 51-66	
474	Response Assessment to Cancer Therapy. 2021 , 249-257	
473	Lung Cancer. 2021 , 481-515	
472	Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. 2021 , 9, 1568	0

471 Remissionsparameter. **2021**, 1-22

470 An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. **2021**, 10, 1984059

469 CT texture analysis as a predictor of favorable response to anti-PD1 monoclonal antibodies in metastatic skin melanoma. **2021**, 0

468 CT-Based Peritumoral and Intratumoral Radiomics as Pretreatment Predictors of Atypical Responses to Immune Checkpoint Inhibitor Across Tumor Types: A Preliminary Multicenter Study. **2021**, 11, 729371 1

467 Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding. **2021**, 32, 1463-1465

466 Immuntherapie bei Kopf-Hals-Plattenepithelkarzinomen. **2021**, 16, 520

465 Classical Mathematical Models for Prediction of Response to Chemotherapy and Immunotherapy. 0

464 The role of immunotherapy in treating lung cancer: current status and future perspective. 0

463 Predictive Value of Multiparametric MRI for Response to Single-Cycle Induction Chemo-Immunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma. **2021**, 11, 734872 1

462 FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma. **2021**, 21, 57 1

461 Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma. **2021**, 11, 19659

460 Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. **2021**, 12, 778459

459 Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the Special Series on Imaging of Inflammation. **2021**, 1

458 Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. **2021**, 12, 721830 9

457 Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis. **2021**, 10, 8272-8287 1

456 A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. **2021**, 158, 17-26 1

455 Response evaluation criteria in solid tumours. 0

454 Complete Remission after Pseudoprogression in Refractory Classical Hodgkin Lymphoma Treated with Pembrolizumab. **2017**, 92, 415-418 1

- 453 Current Advances in Immuno-oncology for Head and Neck Cancer. **2018**, 9, 78-86
- 452 Renal Tumors. **2018**, 1-11
- 451 Therapy: Recommendations for the Oncologists. **2018**, 163-169
- 450 Therapy Monitoring of Oncologic Disease in the Abdomen (Including PET/CT). **2018**, 35-47
- 449 The role of immunotherapy in the treatment of non-small cell lung cancer. **2018**, 12, 185-193
- 448 Toxicités sŕies des immunothŕapies du cancer. **2018**, 27, 522-536
- 447 Improving Clinical Trial Design in Gastrointestinal Oncology. **2019**, 493-507
- 446 Measuring Malignant Pleural Mesothelioma. **2019**, 153-166
- 445 A Case Report of the Clinico-radiologic Challenges of Assessing Treatment Response after Stereotactic Radiation of Oligometastases Preceded by Immunotherapy: Pseudoprogression, Mixed Response Patterns, and Opportunities for Precision Radiation. **2019**, 11, e4264 1
- 444 Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors.
- 443 Critŕies dŕvaluation radiologique des patients sous immunothŕapie. **2019**, 11, S457-S467
- 442 Management of Melanoma Brain Metastasis. **2020**, 281-287
- 441 Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. **2020**, 55-65 0
- 440 Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. **2020**, 57-71
- 439 Tumor pseudoprogression during nivolumab immunotherapy for lung cancer. **2019**, 61, 498-505
- 438 Basics of Cancer Immunotherapy. **2019**, 59, 1119-1121
- 437 Evolution of Response Criteria in Immunotherapy. **2020**, 7-11
- 436 Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors.

- 435 Development of Immunotherapeutic Strategies for Early Phase Clinical Trials. **2020**, 249-282
- 434 Therapy Response Imaging in Gastrointestinal Malignancy. **2020**, 99-115
- 433 Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-program cell death-1/ligand 1 inhibitors.
- 432 Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on Pembrolizumab: A Case Report. **2020**, 12, e7764 3
- 431 Imaging in Melanoma. **2021**, 83-109
- 430 Detection of Immunotherapeutic Response in a Transgenic Mouse Model of Pancreatic Ductal Adenocarcinoma Using Multiparametric MRI Radiomics: A Preliminary Investigation. **2021**, 28, e147-e154 2
- 429 Novel microRNA multivariate biomarkers of response to immunotherapy against HPV E6 oncogene.
- 428 Development of a Flow Cytometry-Based Whole-Blood Prognostic Immune Signature in Metastatic Cancer Patients treated with immune checkpoint inhibitors. 0
- 427 Normative Measurements of Head and Neck Lymph Nodes on Imaging. **2021**, 147-165
- 426 A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). **2021**, 2
- 425 Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. **2021**, 16, e0258988 0
- 424 Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer. **2021**, 4
- 423 Progress and future prospective of FDG-PET/CT imaging combined with optimized procedures in lung cancer: toward precision medicine. **2021**, 36, 1 0
- 422 Therapy Response Imaging in Genitourinary Malignancies. **2020**, 139-157
- 421 Response Assessment and Follow-Up by Imaging in GYN Tumours. **2020**, 517-530
- 420 Cancers bronchiques. **2020**, 139-146.e2
- 419 Response evaluation after immunotherapy in NSCLC: Early response assessment using FDG PET/CT. **2020**, 99, e23815 3
- 418 Important Points to Consider When Evaluating the Response to Drug Therapy for Lung Cancer. **2020**, 60, 942-950

- 417 Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?. **2020**, 9, 2479-2482 1
- 416 Toward radiomics for assessment of response to systemic therapies in lung cancer. **2020**, 11, 4677-4680 0
- 415 Review of PET/CT Images in Melanoma and Sarcoma: False Positives, False Negatives, and Pitfalls. **2021**, 107-129
- 414 Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. **2021**, 38, 89-91
- 413 Response Evaluations for Precision Cancer Therapy and Immunotherapy. **2020**, 15-27
- 412 Cancer Treatment Response to Checkpoint Inhibitors Is Associated with Cytomegalovirus Infection. **2020**, 12, e6670 1
- 411 Evolution of Clinical Trial Imaging and Co-clinical Imaging. **2020**, 239-253
- 410 Efficacy Considerations in Phase I Trials. **2020**, 159-183
- 409 Nuclear Medicine Imaging Techniques in Melanoma. **2020**, 665-683
- 408 Germline HLA-B evolutionary divergence influences the efficacy of immune checkpoint blockade therapy in gastrointestinal cancer. **2021**, 13, 175 1
- 407 Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. **2021**, 10, 2
- 406 Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. **2021**, 12, 6375 0
- 405 An Immunogold Single Extracellular Vesicular RNA and Protein (AuSERP) Biochip to Predict Responses to Immunotherapy in Non-Small Cell Lung Cancer Patients. 0
- 404 Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma. **2021**, 1
- 403 Clinical research progress of immune checkpoint inhibitors in treatment of primary liver cancer. **2020**, 28, 605-616
- 402 Imaging of Treated Liver Tumors and Assessment of Tumor Response to Cytostatic Therapy and Post-Treatment Changes in the Liver. **2021**, 349-373
- 401 Pseudoprogession in lung cancer: a case report. **2020**, 1,
- 400 Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?. **2020**, 12, e10525 0

399	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. 2020 , 04, 373-381	
398	How I Treat Non-Small Cell Lung Cancer Refractory to Immunotherapy. 2020 , 26, 496-501	0
397	Classification of Molecular Biomarkers. 2020 , 1, 8-15	
396	[A Case of Pseudoprogession During Atezolizumab Therapy ?in Lung Adenocarcinoma]. 2019 , 22, 389-394	1
395	[A Case Report on Successful Third Challenge to the Pemetrexed-based Regimen for Advanced Non-small Cell Lung Cancer]. 2019 , 22, 395-400	3
394	How to differentiate pseudoprogession from true progession in cancer patients treated with immunotherapy. 2019 , 9, 1546-1553	34
393	Role of CA19-9 in the prognostic evaluation of SOX neoadjuvant chemotherapy for gastric cancer. 2018 , 11, 5387-5393	1
392	[Combination of Radiation Therapy and Immunotherapy for Non-small Cell Lung Cancer: Peer Exchange on Frontier Academic Topics]. 2020 , 23, 532-540	
391	[Clinical comment of programmed cell death protein 1 immunotherapy for advanced head and neck cancer]. 2020 , 38, 489-494	
390	[Application of Neoadjuvant Immuno-chemotherapy in NSCLC]. 2021 , 24, 284-292	
389	[Chinese Experts Consensus on Immune Checkpoint Inhibitors ?for Non-small Cell Lung Cancer (2020 Version)]. 2021 , 24, 217-235	1
388	Exosomal long noncoding RNA AGAP2-AS1 regulates trastuzumab resistance via inducing autophagy in breast cancer. 2021 , 11, 1962-1981	1
387	Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology. 2021 ,	1
386	Amplification of spatially isolated adenosine pathway by tumor-macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma. 2021 , 14, 200	2
385	Introduction on Nuclear Medicine and Immunology. 2022 , 1-13	0
384	Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival. 2021 , 21, 1246	
383	Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy - single institute experience. 2021 , 55, 482-490	1
382	Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease. 2021 , 13,	0

381	The phenomenon of pseudoprogression in cancer immunotherapy: is everything so unambiguous?. 2021 , 23, 496-500	
380	Early cancer cachexia phenotype predicts survival of advanced urothelial cancer patients treated with pembrolizumab. 2021 ,	
379	Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events. 2021 , 146, 110062	0
378	Adapting Imaging Protocols for PET-CT and PET-MRI for Immunotherapy Monitoring. 2021 , 13,	0
377	The prospect of immunotherapy combined with chemotherapy in patients with advanced non-small cell lung cancer: a narrative review.. 2021 , 9, 1703	2
376	Pseudoprogression in lung cancer patients treated with immunotherapy. 2021 , 169, 103531	4
375	A Machine learning model trained on dual-energy CT radiomics significantly improves immunotherapy response prediction for patients with stage IV melanoma. 2021 , 9,	1
374	Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma. 2021 ,	1
373	Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. 2022 , 61, 114-118	0
372	CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer. 2021 ,	2
371	Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis. 2021 , 11,	3
370	F FDG imaging - response criteria in tumors.. 2021 , 147, 110054	0
369	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. 2021 , 12, 7005	9
368	Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions. 2021 , 101, 108337	0
367	Profiling of immune features to predict immunotherapy efficacy.. 2022 , 3, 100194	2
366	Evaluation of Response to Immune Checkpoint Inhibitors Using a Radiomics, Lesion-Level Approach. 2021 , 13,	0
365	Predictive role of the monocyte-to-lymphocyte ratio in advanced hepatocellular carcinoma patients receiving anti-PD-1 therapy.. 2022 , 11, 160-170	0
364	Pseudoprogresión cutánea por inmunoterapia en melanoma metastásico. 2021 , 66, 288-291	

363	Resistance to Immunotherapy: Mechanisms and Means for Overcoming.. 2021 , 1342, 45-80	0
362	A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. 2021 , 9, 23247096211058489	0
361	Cancer Imaging in Immunotherapy.. 2021 , 1342, 431-447	
360	A Combined-Radiomics Approach of CT Images to Predict Response to Anti-PD-1 Immunotherapy in NSCLC: A Retrospective Multicenter Study.. 2021 , 11, 688679	2
359	Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.. 2022 , 2, 55-63	0
358	Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper.. 2021 , 11, 800547	0
357	Cancer immunomodulation using bispecific aptamers.. 2022 , 27, 894-915	2
356	Clinical outcomes and longitudinal circulating tumor DNA changes after treatment with nivolumab and olaparib in immunotherapy relapsed melanoma with detected homologous recombination deficiency. 2021 , 7,	1
355	Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer.. 2022 , 12, 626	1
354	Immuno-oncology trends: preclinical models, biomarkers, and clinical development.. 2022 , 10,	0
353	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.. 2022 , 21, 20	6
352	Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials.. 2022 ,	0
351	Pseudoprogression of lung large cell neuroendocrine carcinoma resembling pancreatic cancer during durvalumab therapy.. 2022 , 1	0
350	Exploring Response to Immunotherapy in Non-Small Cell Lung Cancer Using Delta-Radiomics.. 2022 , 14,	3
349	NEOADJUVANT IMMUNOTHERAPY IN HEAD AND NECK CANCER: RATIONALE, CURRENT EVIDENCE AND FUTURE PERSPECTIVE. 2021 , 103569	5
348	Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma.. 2021 , 11, 796197	2
347	Molecular response assessment with immune adaptive positron emission tomography response criteria in solid tumors in lung cancer patients treated with nivolumab: Is it better than immune response evaluation criteria in solid tumors?. 2022 ,	
346	Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence.. 2022 , 1	0

- 345 PET Imaging of Melanoma. **2022,**
- 344 Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead.. **2022, 12, 789728** 0
- 343 A radiomics model predicts the response of patients with advanced gastric cancer to PD-1 inhibitor treatment.. **2022, 14, 907-922** 0
- 342 Predicting treatment outcomes using F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy.. **2022, 14, 17588359211068732** 1
- 341 Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.. **2022, 45,** 0
- 340 The Future of Artificial Intelligence Applied to Immunotherapy Trials. **2022, 265-284**
- 339 Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.. **2022, 10,** 0
- 338 Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group.. **2021, 164, 76-83** 0
- 337 Outcome Prediction at Patient Level Derived from Pre-Treatment 18F-FDG PET Due to Machine Learning in Metastatic Melanoma Treated with Anti-PD1 Treatment.. **2022, 12,** 0
- 336 Immune checkpoint inhibitors rechallenge in urological tumors: An extensive review of the literature.. **2022, 170, 103579** 2
- 335 RECISTSup: Weakly-supervised Lesion Volume Segmentation using RECIST Measurement.. **2022, PP,**
- 334 Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial.. **2022, 23, 137** 0
- 333 Repurposing azacitidine and carboplatin to prime for anti-PDL1 re-challenge of immunotherapy-resistant melanoma.
- 332 The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.. **2021, 600, 727-730** 36
- 331 Methoden klinischer Prfung in der Onkologie. **2021, 1-53**
- 330 Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab.. **2022, 113, 295-350** 1
- 329 Teaching cancer imaging in the era of precision medicine: Looking at the big picture.. **2022, 9, 100414** 0
- 328 Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma.. **2022,** 1

327	Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival.. 2022 , 10,	2
326	Early dynamics of circulating tumor DNA predict clinical response to immune checkpoint inhibitors in metastatic renal cell carcinoma.. 2022 ,	0
325	Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice.. 2022 ,	0
324	Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?. 2022 , 11,	0
323	Immunotherapy for the treatment of perineural spread in cutaneous head and neck squamous cell carcinoma: Time to rethink treatment paradigms.. 2022 ,	0
322	F-FDG PET/CT features of immune-related adverse events and pitfalls following immunotherapy.. 2022 ,	2
321	PKC ζ /ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma.. 2022 ,	1
320	Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.. 2022 , 12,	
319	The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials.. 2022 ,	0
318	Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer.. 2022 , 14,	3
317	Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.. 2022 , 5, e2149040	4
316	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade.. 2022 , 5,	2
315	Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125.. 2022 , 2022, 8401202	2
314	Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center.. 2022 , 14,	
313	Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.. 2022 ,	0
312	Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.. 2022 ,	
311	Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.. 2022 , 1	
310	Evolution of bone metastases in patients receiving at least three months of checkpoint inhibitors.. 2022 , 1	

309	C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.. 2022 , 10,	2
308	Organ-Specific and Mixed Responses to Pembrolizumab in Patients with Unresectable or Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study.. 2022 , 14,	1
307	The Potential of Photoacoustic Imaging in Radiation Oncology.. 2022 , 12, 803777	1
306	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. 2022 , JCO2102583	4
305	Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.. 2022 ,	1
304	Editorial to the Special Issue Entitled "Imaging in Immunooncology".. 2022 , 24, 177	0
303	A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer.. 2022 ,	2
302	DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.. 2022 , 10,	2
301	Artificial Intelligence-based Radiomics in the Era of Immuno-Oncology.. 2022 ,	0
300	Prediction of Early Response to Immunotherapy: DCE-US as a New Biomarker.. 2022 , 14,	
299	Molecular Response Assessment with Immune Adaptive PERCIST in Lung Cancer Patients Treated with Nivolumab: Is It Better Than iRECIST?. 2022 , 21, 34-43	
298	Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.. 2022 , 12, 5448	0
297	Prognostic Utility of Parameters Derived From Pretreatment Dual-Layer Spectral-Detector CT in Patients With Metastatic Renal Cell Carcinoma.. 2021 ,	1
296	Circulating Immune Bioenergetic, Metabolic, and Genetic Signatures Predict Melanoma Patients' Response to Anti-PD-1 Immune Checkpoint Blockade.. 2022 , 28, 1192-1202	0
295	Hyperprogressive disease in leiomyosarcoma: a threat to the use of single-agent anti-PD-(L)1 therapy?. 2022 ,	0
294	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0.. 2022 , 1	5
293	Elevated tumor markers for monitoring tumor response to immunotherapy.. 2022 , 46, 101381	
292	Cell-Free Tumor DNA (cf-tDNA) Liquid Biopsy: Current Methods and Use in Brain Tumor Immunotherapy.. 2022 , 13, 882452	1

291	Imaging immunity in patients with cancer using positron emission tomography.. 2022 , 6, 24	0
290	Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer.. 2022 ,	
289	Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs.. 2022 , 167, 42-53	1
288	Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST?. 2021 , 8, 771887	0
287	Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials.. 2021 , 14,	0
286	A Case of Recurrence of HER2-Positive Esophagogastric Junction Cancer in Which Fourth-Line Treatment with Nivolumab Was Effective after Pseudo Progression-Like Growth. 2021 , 54, 853-860	
285	Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.. 2021 , 47, 969	2
284	Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.. 2021 , 11, 764189	3
283	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer-A Review.. 2021 , 14,	3
282	First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes. 2021 , 13,	2
281	Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. 2021 , 2,	0
280	Effectiveness and safety of pembrolizumab monotherapy in patients with locally advanced or metastatic non-small-cell lung cancer.. 2021 , 10781552211061117	
279	A Case of Lung Adenocarcinoma Responding to Ramucirumab and Docetaxel After Rapid Tumor Growth Following Pembrolizumab Treatment. 2021 , 61, 970-974	0
278	[F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma.. 2021 , 49, 2010	0
277	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. 2021 , 4, 258-270	0
276	Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis.. 2021 , 2841851211065935	0
275	Neoadjuvant treatment strategies for hepatocellular carcinoma.. 2021 , 13, 1550-1566	2
274	A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning.. 2022 , 9, 880326	0

273	Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types.. 2022 , 1	1
272	Association of thyroid function abnormality and prognosis in non-small-cell lung cancer patients treated with PD-1 inhibitors.. 2022 ,	0
271	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients With Advanced Refractory Solid Tumors.. 2022 ,	3
270	iRECIST-based versus non-standardized free text reporting of CT scans for monitoring metastatic renal cell carcinoma: a retrospective comparison.. 2022 , 1	
269	Acquired resistance to anti-PD1 therapy in patients with NSCLC reveals changes in T cell phenotypes and MET amplification.	
268	Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition.. 2022 , 12, 830627	1
267	Feasibility of double sleeve lobectomy after neoadjuvant chemotherapy in patients with non-small cell lung cancer.. 2022 ,	0
266	Data_Sheet_1.pdf. 2020 ,	
265	Image_1.JPEG. 2019 ,	
264	Image_2.JPEG. 2019 ,	
263	Table_1.DOCX. 2019 ,	
262	Table_1.docx. 2020 ,	
261	Table_2.docx. 2020 ,	
260	Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade.. 2022 , 14, 17588359221096877	1
259	OUP accepted manuscript.	2
258	Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival.. 2022 , 15, 56-66	0
257	Functional imaging for evaluation of cancers and biologically conformal radiotherapy: Past-history and present-day perspectives.. 2022 , 104124	0
256	Expression of CD274 mRNA Measured by qRT-PCR Correlates With PD-L1 Immunohistochemistry in Gastric and Urothelial Carcinoma.. 2022 , 12, 856444	1

255	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab.. 2022,	1
254	Clinical and Biological Variables Influencing Outcome in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Anti-PD-1/PD-L1 Antibodies: A Prospective Multicentre Study. 2022, 12, 679	1
253	Deciphering radiological stable disease to immune checkpoint inhibitors.. 2022,	0
252	CD20+CD22+ADAM28+ B Cells in Tertiary Lymphoid Structures Promote Immunotherapy Response. 2022, 13,	0
251	Immunotherapy-Based Treatments of Hepatocellular Carcinoma: Expert Panel Narrative Review.. 2022,	1
250	Development of a Clinically Oriented Model to Predict Antitumor Effects after PD-1/PD-L1 Inhibitor Therapy.. 2022, 2022, 9030782	1
249	Evaluation of the Effects of Anti-PD-1 Therapy on Triple-Negative Breast Cancer in Mice by Diffusion Kurtosis Imaging and Dynamic Contrast-Enhanced Imaging.. 2022,	1
248	Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients.. 2022,	1
247	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer.. 2022, 108, 108803	0
246	Prognostic value of immunotherapy-induced organ inflammation assessed on FDG PET in patients with metastatic non-small cell lung cancer.. 2022, 1	
245	Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway.. 2022, 20, 225	0
244	OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.. 2022, 108, 108813	1
243	CPI Adult Cancer Imaging Special Edition Module. 2019,	
242	Update in TIGIT Immune-Checkpoint Role in Cancer. 2022, 12,	1
241	Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature. 2022, 13,	1
240	CPI Chest Radiology Module 2019. 2019,	
239	Role of radiomics in predicting immunotherapy response.. 2022,	1
238	Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab. 2022, 8, 1363-1373	1

- 237 Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies. ○
- 236 Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma. **2022**, 1-22 ○
- 235 Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. *Lancet Oncology, The*, **2022**, 21.7 3
- 234 Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. **2022**, 10, e003956 ○
- 233 Indonesian consensus on systemic therapies for hepatocellular carcinoma.
- 232 A Role for PET/CT in response assessment of malignant pleural mesothelioma. **2022**, ○
- 231 Combination of Stereotactic Ablative Radiotherapy With Anti-PD-1 in Oligoprogressive Non-Small-Cell Lung Cancer And Melanoma: Results of a Prospective Multicenter Observational Study. **2022**, ○
- 230 FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients. **2022**, ○
- 229 FFCO 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. **2022**, ○
- 228 BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours. **2022**, 12, e060342 ○
- 227 Identification of non-small cell lung cancer (NSCLC) patients who benefit from treatment beyond progression with pembrolizumab from individual lesion response dynamics.
- 226 Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. Volume 9, 517-536
- 225 Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. **2022**, 41, 4
- 224 Standardized Reporting of Oncologic Response: Making Every Report Count. **2022**, 4, ○
- 223 Imaging response assessment for oncology: An algorithmic approach. **2022**, 9, 100426 ○
- 222 Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope. **2022**, 393-411
- 221 Novel Imaging Biomarkers to Assess Oncologic Treatment-Related Changes. **2022**, 1-13 ○
- 220 Perspectives on imaging and immunotherapy: a review series. **2022**, 10, e005006 ○

219	Minireview. 2022 , 101983	0
218	Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors. 2022 , 10, e004495	2
217	Complete and long-lasting response to immunotherapy. 2022 , 101, e28940	0
216	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. 2022 , 27, 3798	5
215	Case report: pathological complete response in an IIIB non-small cell lung cancer patient after preoperative neoadjuvant nivolumab therapy combined with chemotherapy. 2022 , 101, e29336	
214	Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.	
213	Immunotherapy in advanced non-small-cell lung cancer (NSCLC) after progression on chemotherapy: real-world results from a prospective institutional cohort.	0
212	Phase IIb study of pembrolizumab combined with S-1 + oxaliplatin or S-1 + cisplatin as first-line chemotherapy for gastric cancer.	1
211	Plac1 Remodels the Tumor Immune Evasion Microenvironment and Predicts Therapeutic Response in Head and Neck Squamous Cell Carcinoma. 12,	
210	iRECIST and atypical patterns of response to immuno-oncology drugs. 2022 , 10, e004849	1
209	Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. 2022 , 14, 3092	0
208	Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. 2022 , 176, 103746	
207	Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy. 13,	
206	Criteria for assessing the response to treatments in solid tumor in the era of new oncology: what radiologists should know. 2022 , 9,	
205	Clinical Efficacy of Image-Guided Radiation Therapy for Cervical Cancer and Its Impact on Patients' Serum Tumor Markers and KPS Scores. 2022 , 2022, 1-5	0
204	Noninvasive interrogation of CD8+ T cell effector function for monitoring tumor early responses to immunotherapy.	1
203	Multimodal Therapies Against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches Towards Ultimate Nanomedicine Treatments. 2200079	2
202	In search of effective therapies: the current landscape of phase II trials in patients with advanced soft tissue sarcoma.	0

201	Early Response Assessment in Advanced Stage Melanoma Treated with Combination Ipilimumab/Nivolumab. 13,	0
200	Management of cutaneous melanoma: radiologists challenging and risk assessment.	6
199	Novel biomarkers in NSCLC: Radiomic analysis, kinetic analysis, and circulating tumor DNA. 2022 ,	
198	Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors. 9,	1
197	Clinical outcomes of hyperprogression based on volumetry in non-small cell lung cancer after immune checkpoint inhibitor treatment.	0
196	Visualizing T cells by very late antigen-4-targeted positron emission tomography.	
195	Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancers. 2022 , 41,	1
194	Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer.	0
193	Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy. 2022 , 17, e0270950	
192	Assessing Response to Therapy. 2023 , 28-38	
191	Melanoma. 2023 , 630-655	
190	Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.	1
189	Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?. 2022 , 10, e004848	1
188	Effectiveness and Safety of PD-1 Inhibitor Monotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Exploratory Study. 2022 , 2022, 1-10	0
187	Tumour treating fields. 2022 , 269-283	
186	Assessment of clinical studies evaluating combinations of immune checkpoint inhibitors with locoregional treatments in solid tumors. 2022 ,	0
185	Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China. 13,	0
184	Bintrafusp alfa, an anti-PD-L1:TGF- β trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer.	2

183	Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting. 2022 , 14, 3968	1
182	Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade Resistant Melanoma for Anti-PD-L1 Rechallenge. 2022 , 2, 814-826	0
181	Efficacy of nivolumab as second line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a national DAHANCA cohort study. 2022 , 61, 972-978	0
180	The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study.	
179	Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054. OF1-OF20	0
178	The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.	2
177	Hyperprogressive disease in patients suffering from solid malignancies treated by immune checkpoint inhibitors: A systematic review and meta-analysis. 12,	
176	Identification of clinical and ecological determinants of strain engraftment after fecal microbiota transplantation using metagenomics. 2022 , 3, 100711	0
175	Nanomaterials for Natural Killer Cell-Based Immunoimaging and Immunotherapies in Cancer.	0
174	Early complete tumor response as a survival predictor in hepatocellular carcinoma patients receiving stereotactic body radiation therapy. 2022 ,	
173	Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer. 2022 , 2022, 1-8	0
172	Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. 2022 , 20,	0
171	Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art. 2022 , 14, 4093	0
170	Immunotherapy and Interventional Radiology: Two Optimal Allies in the Management of Bronchial Cancer.	
169	First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan. 2022 , 3, 100397	1
168	Safety and efficacy of lenvatinib combined with camrelizumab plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A two-center retrospective study. 12,	0
167	Assessment and Monitoring of Response to Systemic Treatment in Advanced Hepatocellular Carcinoma: Current Insights. Volume 9, 1011-1027	0
166	MRI techniques for immunotherapy monitoring. 2022 , 10, e004708	0

165	Imaging to predict checkpoint inhibitor outcomes in cancer. A systematic review. 2022 , 175, 60-76	0
164	Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment. 2022 , 175, 136-157	5
163	Interval design to identify the optimal biological dose for immunotherapy. 2022 , 30, 101005	0
162	Comparing [18F]FDG PET/CT response criteria in melanoma and lung cancer patients treated with immunotherapy: a systematic review.	0
161	Abscopal Response in Metastatic Melanoma: Real-World Data of a Retrospective, Multicenter Study. 2022 , 14, 4213	1
160	DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment.	0
159	Monitoring of Current Cancer Therapy by Positron Emission Tomography and Possible Role of Radiomics Assessment. 2022 , 23, 9394	1
158	The Role of Stereotactic Radiotherapy in the Management of Melanoma, A Retrospective Single Institute Preliminary Study of 30 Patients. 28,	0
157	Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. 2022 , 105457	0
156	Echocardiography-Assessed Changes of Left and Right Ventricular Cardiac Function May Correlate with Progression of Advanced Lung Cancer: A Generating Hypothesis Study. 2022 , 14, 4770	2
155	Preclinical Characterization and Phase 1 Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies.	1
154	KEYNOTE ID36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.	1
153	Variability of strain engraftment and predictability of microbiome composition after fecal microbiota transplantation across different diseases. 2022 , 28, 1913-1923	1
152	A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma. 2022 , 13,	2
151	Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.	0
150	PD-1/PD-L1 immune-checkpoint blockade induces immune effector cell modulation in metastatic non-small cell lung cancer patients: A single-cell flow cytometry approach. 12,	0
149	An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. 2022 , 11,	1
148	Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. 13,	0

147	Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.	0
146	Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy. 1-12	0
145	Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy. 10,	0
144	Cancer Immunotherapy Clinical Trials. 2022 , 1-24	0
143	Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients. 2022 , 14, 175883592211315	0
142	Specific characteristics of the magnetic resonance imaging for transarterial chemoembolization with drug-saturated microspheres in oncogynecology.	0
141	Early Effects of Nivolumab and Ipilimumab Combined Immunotherapy in the Treatment of Metastatic Melanoma in Poland: A Multicenter Experience. 2022 , 10, 2528	1
140	Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume. 12,	0
139	Tumor response assessment on imaging following immunotherapy. 12,	0
138	Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy.	0
137	Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. 2022 , 21, 135-141	0
136	Cancer Immunotherapy. 1-22	0
135	PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy. 13,	1
134	Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients. 2,	0
133	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. 2022 , 28, 583-705	3
132	Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. 2022 , 14, 5078	1
131	IGFBP1hiWNT3Alo Subtype in Esophageal Cancer Predicts Response and Prolonged Survival with PD-(L)1 Inhibitor. 2022 , 11, 1575	0
130	Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer.	0

129	Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial.	0
128	The diagnosis, classification, and treatment of sarcoma in this era of artificial intelligence and immunotherapy.	1
127	Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. 2022 , 14, 4974	2
126	Molecular hallmarks of cancer. 2023 , 489-505.e5	0
125	Empowering drug development: leveraging insights from imaging technologies to enable the advancement of digital health technologies.	0
124	Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients. 12,	0
123	The radiological appearances of lung cancer treated with immunotherapy: a review.	0
122	Nanotheranostic Strategies for Cancer Immunotherapy. 2200718	0
121	The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints. 2022 , 10, 2827	0
120	Five-gene Signature for the Prediction of Response to Immune Checkpoint Inhibitors in Patients with Gastric and Urothelial Carcinomas. 2022 , 154233	0
119	Serum C-Reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab Plus Nivolumab. 2022 , 14, 5659	1
118	Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis. 2023 , 47, 58-64	0
117	Emerging and Evolving Concepts in Cancer Immunotherapy Imaging. 2023 , 306, 32-46	1
116	New synthetic nano-immunotherapy (OncoTherad [®]) for non-muscle invasive bladder cancer: Its synthesis, characterization and anticancer property. 2023 , 80, 101988	0
115	Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival. 2023 , 39, 100558	0
114	2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. 2022 , 23, 1126	4
113	Immunotherapy. 2022 , 309-328	0
112	Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term One Stop Therapeutic Shop [®] Volume 15, 1409-1415	0

111	Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.	0
110	Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.	2
109	Modern aspects of immunotherapy with checkpoint inhibitors in melanoma. 2022 , 35-40	0
108	Imaging endpoints for clinical trial use: a RECIST perspective. 2022 , 10, e005092	0
107	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.	0
106	IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. 2022 ,	3
105	Clinical Outcomes in COVID-19 Patients Treated with Immunotherapy. 2022 , 14, 5954	0
104	Mathematical modeling of cancer immunotherapy for personalized clinical translation. 2022 , 2, 785-796	0
103	Ita-immuno-pet: the Role of Fdg Pet/ct for Assessing Response to Immunotherapy.	0
102	Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.	2
101	Immune Checkpoint Inhibitor Therapy in Oncology. 2022 , 4, 579-597	2
100	Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ- PBMC-HPV) in HLA-A*02+ patients with HPV16+ Solid Tumors.	0
99	Transarterial chemoembolisation plus I125 seeds implantation for people with unresectable hepatocellular carcinoma. 2022 , 2022,	0
98	Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma. 2022 , 5, e2246400	0
97	Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. 2022 , 22,	0
96	Estimated Costs of the Ipilimumab+Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. 2023 , 15, 31	0
95	Differentially Expressed Genes and Signaling Pathways Potentially Involved in Primary Resistance to Chemo-Immunotherapy in Advanced-Stage Gastric Cancer Patients. 2023 , 24, 1	0
94	Assessment of immunotherapy response in intracranial malignancy using semi-automatic segmentation on magnetic resonance images. 13,	0

93	Dual-energy computed tomography as a lower radiation dose alternative to perfusion computed tomography in tumor viability assessment. 2023 , 13,	0
92	Deep learning-based Segmentation of Multi-site Disease in Ovarian Cancer.	0
91	Immunotherapy Assessment: A New Paradigm for Radiologists. 2023 , 13, 302	1
90	Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies. 2023 , 11, 238	0
89	Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. 2023 , 15, 321	2
88	Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC. 2023 , 23,	0
87	Efficacy And Safety Of Nivolumab In Bone Metastases From Renal Cell Carcinoma: Results Of The Getug Afu 26 Nivoren Multicenter Phase Ii Study.. 2023 ,	0
86	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. 13,	0
85	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. 13,	0
84	A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.	0
83	Norepinephrine inhibits CD8+ T-cell infiltration and function, inducing anti-PD-1 mAb resistance in lung adenocarcinoma.	0
82	Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial.	0
81	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023 ,	0
80	Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer. 2023 , 12, 258	0
79	Evaluation of the effectiveness of transarterial chemoembolization with drug-saturable microspheres with irinotecan for the treatment of patients with neuroendocrine tumors with liver metastases..	0
78	CT-based delta radiomics in predicting the prognosis of stage IV gastric cancer to immune checkpoint inhibitors. 12,	0
77	Going big by going small: Trade-offs in microbiome explanations of cancer. 2023 , 97, 101-110	0
76	Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). 2023 , 15, 254	0

- 75 Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer. **2022**, 12, ○
- 74 Roadmap for Precision preclinical x-ray radiation studies. ○
- 73 Significance of second progression-free survival in patients with advanced urothelial cancer who received platinum-based combination chemotherapy followed by pembrolizumab. ○
- 72 Grundlagen der medikamentösen Tumorthherapie. **2022**, 1-23 ○
- 71 Radiologic assessment of tumor response to immunotherapy and its complications. **2023**, 239-261 ○
- 70 Alkaline phosphatase combined with α -glutamyl transferase is an independent predictor of prognosis of hepatocellular carcinoma patients receiving programmed death-1 inhibitors. 14, ○
- 69 [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. **2023**, 1-40 ○
- 68 Quality improvements in radiation oncology clinical trials. 13, ○
- 67 ITA-IMMUNO-PET: The Role of [18F]FDG PET/CT for Assessing Response to Immunotherapy in Patients with Some Solid Tumors. **2023**, 15, 878 ○
- 66 Imaging Recommendations for Diagnosis, Staging, and Management of Lung Cancer. ○
- 65 Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers. 12, ○
- 64 Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients' Outcomes?. **2023**, 15, 793 ○
- 63 Benign and Malignant Renal Disease. **2023**, 153-168 ○
- 62 Evaluation and Prediction of Treatment Response for Hepatocellular Carcinoma. **2023**, 22, 209-220 ○
- 61 Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. **2023**, 24, 4302 ○
- 60 Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—An exploration of surrogate endpoint. **2023**, 23, ○
- 59 The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. **2023**, 14, ○
- 58 Tyrosine kinase inhibitors as potential sensitizers of adoptive T cell therapy for hepatocellular carcinoma. 14, ○

- 57 Nonoperative Management of dMMR/MSI-H Colorectal Cancer following Neoadjuvant Immunotherapy: A Narrative Review. ○
- 56 Randomized phase II trial in prostate cancer with hormone-sensitive Oligometastatic relapse: Combining stereotactic ablative radiotherapy and durvalumab (POSTCARD GETUG P13): Study protocol. **2023**, 40, 100613 ○
- 55 IFN- γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics. **2023**, ○
- 54 A phase 1 trial of NY-ESO -1-specific TCR -engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma. **2023**, 152, 2554-2566 ○
- 53 First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. **2023**, 29, 473-482 ○
- 52 Immunotherapy combined with chemotherapy in the treatment for rare primary mucoepidermoid carcinoma of the liver: a case report. **2023**, 34, 582-588 ○
- 51 Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on Immunotherapy. ○
- 50 A case of hepatocellular carcinoma with pseudoprogression followed by complete response to atezolizumab plus bevacizumab. ○
- 49 Safety and efficacy of Pucotenlimab (HX008) - a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase II study. **2023**, 23, ○
- 48 Image-based response assessment during immunotherapy in skin cancer. **2023**, 21, 107-114 ○
- 47 Circulating IL-6 is associated with disease progression in BRAFwt metastatic melanoma patients receiving anti-PD-1 therapy. jcp-2022-208615 ○
- 46 Efficacy and safety of anti-PD-1 antibody plus chemoradiotherapy in locally advanced esophageal squamous cancer. 13, ○
- 45 Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer. 12, ○
- 44 A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. **2023**, ○
- 43 Immunotherapy in breast cancer: an overview of current strategies and perspectives. **2023**, 9, 1 ○
- 42 Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors. **2023**, 21, 133-142.e3 ○
- 41 Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial. **2023**, 178, 183-190 ○
- 40 Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. **2023**, 11, e005854 ○

- 39 Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. **2023**, 30, 2366-2387 ○
- 38 Bildgestützte Beurteilung des Ansprechens auf Immuntherapien bei Hauttumoren. **2023**, 21, 107-115 ○
- 37 Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment. **2023**, 13, 793 ○
- 36 Immune checkpoint inhibitor using in cases with gestational trophoblastic diseases. **2023**, 40, ○
- 35 Immune checkpoint inhibitors for advanced pancreatic cancer. **2023**, 2023, ○
- 34 Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171). **2023**, ○
- 33 Efficacy and safety of preoperative immunotherapy in patients with mismatch repair-deficient or microsatellite instability-high gastrointestinal malignancies. 15, 222-233 ○
- 32 Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. **2023**, 24, e133-e143 ○
- 31 Neoplastic Diseases of the Respiratory System in Geriatric Patients. **2023**, 171-216 ○
- 30 Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors. **2023**, 11, 749 ○
- 29 Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors. ○
- 28 ⁸⁹Zr-immuno-PET using the anti-LAG-3 tracer [⁸⁹Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCC. ○
- 27 Precision Surgery in NSCLC. **2023**, 15, 1571 ○
- 26 Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours. **2023**, 23, ○
- 25 Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients. **2023**, 21, ○
- 24 [¹⁸F]FDG PET/CT in the Evaluation of Melanoma Patients Treated with Immunotherapy. **2023**, 13, 978 ○
- 23 Imaging Recommendations for Diagnosis, Staging, and Management of Cervical Cancer. **2023**, 44, 119-129 ○
- 22 The effect of combining PD-1 agonist and low-dose Interleukin-2 on treating systemic lupus erythematosus. 14, ○

- 21 Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy. ○
- 20 Pseudoprogression and Mixed Responses in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: A Retrospective Analysis. **2023**, ○
- 19 Immunotherapy Success for Microsatellite Stable Colorectal Cancers Searching for the Horizon. ○
- 18 Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. ○
- 17 Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors. **2023**, 11, e005921 ○
- 16 Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer. **2023**, 13, 526 ○
- 15 Advanced CT Imaging, Radiomics, and Artificial Intelligence to Evaluate Immune Checkpoint Inhibitors Effects on Metastatic Renal Cell Carcinoma. **2023**, 13, 3779 ○
- 14 Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging. **2023**, 31-45 ○
- 13 Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup. **2023**, ○
- 12 Patterns of Response to Immune Oncology Drugs: How Relevant Are They in SCCHN?. **2023**, 217-228 ○
- 11 Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study. **2023**, 13, 877 ○
- 10 Response Evaluation of Neoadjuvant Therapies in Sarcoma. ○
- 9 A SPONTANEOUS MELANOMA MOUSE MODEL APPLICABLE FOR A LONGITUDINAL CHEMOTHERAPY AND IMMUNOTHERAPY STUDY. **2023**, ○
- 8 Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas. 14, ○
- 7 PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. 1 ○
- 6 Identification of a novel peptide targeting TIGIT to evaluate immunomodulation of 125I seed brachytherapy in HCC by near-infrared fluorescence. 13, ○
- 5 Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer. ○
- 4 Prolonged Survival in a Patient With Extensive-Stage Small Cell Lung Cancer in Spite of Discontinued Immunotherapy With Atezolizumab. **2023**, ○

- 3 Procedural technique development. **2023**, 81-86 ○
- 2 Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. ○
- 1 Immune-related thyroid dysfunctions during anti PD-1/PD-L1 inhibitors: new evidence from a single centre experience. ○